Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2012 Feb 10.
Published in final edited form as: Nanoscale. 2010 Oct 26;3(2):335–353. doi: 10.1039/c0nr00485e

Nanoscale surface modifications of medically-relevant metals: state-of-the art and perspectives

Fabio Variola 1,2, John Brunski 3, Giovanna Orsini 4, Paulo Tambasco de Oliveira 5, Rima Wazen 2, Antonio Nanci 2,*
PMCID: PMC3105323  NIHMSID: NIHMS293771  PMID: 20976359

Abstract

Evidence that nanoscale surface properties stimulate and guide various molecular and biological processes at the implant/tissue interface is fostering a new trend in designing implantable metals. Cutting-edge expertise and techniques drawn from widely separated fields, such as nanotechnology, materials engineering and biology, have been advantageously exploited to nanoengineer surfaces in ways that control and direct these processes in predictable manners. In this review, we present and discuss the state-of-the-art of nanotechnology-based approaches currently used to modify the surface of metals used for orthopedic and dental applications, and also briefly consider their use in the cardiovascular field. The effects of nanoengineered surfaces on various in vitro molecular and cellular events are firstly discussed. Importantly, this review also provides an overview of in vivo and clinical studies with nanostructured metallic implants, and addresses the potential influence of nanotopography on biomechanical events at interfaces. Ultimately the objective of this work is to give the readership a comprehensive picture of the current advances, future developments and challenges in the application of the infinitesimally small to biomedical surface science. We believe that an integrated understanding of the in vitro and particularly of the in vivo behavior is mandatory for the proper exploitation of nanostructured implantable metals and, as a matter of fact, all biomaterials.

1. Introduction

Current generations of dental and orthopedic implants are relatively effective but they still need significant improvement, particularly in their capacity to selectively influence and guide cell and tissue events at the implantation site. Their longevity is limited, and their success depends on the patient’s overall health. The benefit of better mastication offered by implant-supported prostheses not only improves the quality of life but also has an impact on the overall health of the patient. Dental implants are generally limited to patients with “good bone quality”, leaving out a large segment of the population that has lost supporting jaw bone with age. In orthopedics, there is an increasing number of cases of total hip replacement to treat advanced degenerative changes (such as those caused by arthritis and osteonecrosis), as well as fractures in patients with osteoporosis. Here, also overall bone status plays a major role in securing both short- and long-term implant stability. The growing frequency of joint replacements, not only in a population that lives longer but also in younger people, has led to an increasing number of patients requiring revision surgery, with the average implant needing replacement approximately every 10 years.1 The need for revision surgery typically arises from loss of bone supporting the prosthesis (osteolysis). Because of the additional bone loss and restructuring at the surgical site, revisions are more difficult to perform and generally result in less support for the prosthesis and poorer overall outcomes than the original surgery. Most importantly for the patient, they are associated with higher morbidity. In addition, they are extremely costly for health providers and a significant drain on healthcare resources in terms of surgeon time and post-surgery care of patients. Hip replacements are familiar examples, but there are similar needs for improved procedures for knee and spine implants.

Similarly, each year millions of individuals undergo balloon angioplasty to unblock arteries. In the U.S., about 80% of them also receive a self-expanding, metal mesh tube, called a stent, intended to prevent renarrowing of blood vessels after they have been reopened.2 Balloon angioplasty has been performed since the late 1970’s, but coronary stents were only introduced in the early 1990’s. Major problems associated with stents are thrombosis and closure of the blood vessel after surgery (restenosis), the latter occurring in up to 30% of patients.2 A promising development in stent technology is the advent of drug-eluting stents (DESs), whose surface is coated with polymers containing agents that regulate cell division and prevent clot formation. So far, clinical results with DESs are encouraging; however, there are still problems with this technology. For instance, the polymer coating may weakly adhere, cause inflammation and increase the propensity for thrombosis.3

Different classes of materials (metals, ceramics, polymers and composites) are currently used to manufacture prosthetic implants and biomedical devices.4 However, metals still represent the gold standard in implantology because of their mechanical properties, resistance to corrosion and biocompatibility,4, 5 which can be defined as the ability of a material to accomplish specific biomedical functions without causing adverse immune and tissue reactions. Stainless steels (such as 316L) as well as titanium and its alloys (such as TiAl and shape-memory TiNi alloys) are widely encountered in orthopedics, dentistry and cardiology.57 In addition, because of their low friction coefficient and high wear resistance, CrCo alloys are also currently used to manufacture components of knee and hip joints.8, 9 For implantation in the spine, tantalum has been exploited to create three-dimensional porous structures that favor bone ingrowth for a more effective osseointegration.10

Degradable metallic biomaterials (DMMs), such as magnesium- and iron-based alloys, are increasingly gaining interest for skeletal and cardiovascular applications (e.g. wires, fixation plates, stents) which do not require the permanent presence of an implanted device.11 They essentially have the capacity to provide specific functions (e.g. structural support, favoring the healing process) and dissolve through corrosion afterwards, without generating toxic by products.12, 13

Progress in nanotechnology now makes it possible to precisely design and modulate at the nanoscale the surface properties of materials used for various applications in medicine, offering new prospects for the patient.14, 15 Nanoengineered surfaces possess the unique capacity of directly affecting the molecular and cellular events that ultimately determine the overall biological response to an implanted material, such as protein adsorption, cell adhesion and proliferation among others.1620 As a result of this exceptional ability, various nanotechnology-based techniques have been developed to generate nanoscale surface features on existing biocompatible materials (reviewed in references 14, 15).

Due to their extensive use in medicine and to their potential for future biomedical applications, metals have been given a particular attention (reviewed in reference 21). Therefore, in this review paper, we bring attention to methods currently used for nanostructuring the surfaces of implantable metals, highlighting in particular those approaches that offer a clinical applicability or that have already resulted in commercial devices in the orthopedic and dental fields. We then provide evidence of the enhanced biological activity achieved with nanotechnology-based surface modifications by presenting an overview of in vitro studies on how cells respond to nanostructured metallic surfaces. In this context, unlocking the precise mechanisms which govern cell-substrate interactions will ultimately permit to endow implantable metals with the exact physicochemical properties needed to elicit a specific biological outcome (e. g. osseointegration, anticoagulation, etc). However, although essential in the progress of biological surface science and in the development of the future generation of implantable materials, in vitro experiments, as it is well recognized in biomedical sciences, only reflect part of the multifactorial and dynamic biological environment of living organisms. This translates into the need to ultimately complete the study and evaluate the performance of a biomaterial in vivo, an aspect that is often forgotten or just briefly discussed in review articles on nanostructured materials. Such oversight must be addressed, and this work is meant to take a step in this direction by illustrating not only the in vitro outcomes, but by also integrating the in vivo biological and biomechanical performances of nanoengineered implants. We ultimately bring attention to some important considerations we believe need to be made to correlate in vitro conditions with the in vivo reality, concluding with our perspectives for the future development of improved metals for biomedical applications.

2. Approaches for nanoscale surface modification

The surface properties of implantable metals can be modified on a range of scales by various techniques.22, 23 Various approaches have been used so far to create micron-scale topographies on the surface of biocompatible metals.2426 Although the resulting surface features demonstrated to be effective in enhancing in vitro2729 and in vivo3033 biological events, it is now recognized that material-host tissue interactions are principally governed by nanometric surface cues.14, 16, 17, 34, 35 As a consequence, micron-scale features can only at best have an indirect influence on cellular activity and thereby can inherently only have limited activity and success. Therefore, there is a need for surface features that can have a more direct and rapid outcome. To this end, various strategies have been devised and implemented to nanoengineer surfaces that can directly influence the biological functionalities of implantable metals.14, 21 Only some of these methods, however, can at this time be easily exported to a large-scale production for medical implant manufacturing. In this section, we therefore present the approaches that have the potential for industrial exploitation. These techniques, divided into chemical and physical methods, have been selectively chosen according to the following parameters, necessary for large-scale manufacturing: (1) ability to simultaneously reach all surfaces in devices with complex geometries (e. g. femoral stems, dental screws and cardiovascular stents); (2) possibility to modify at the nanoscale commercially-available biocompatible metals and implants; and (3) simple integration in the industrial process line.

2.1 Chemical methods

Electrochemical modification is one of the most common and flexible ways to modify metallic surfaces on the nanoscale.36 Anodic oxidation has been successfully used to transform smooth titanium surfaces into nanotubular structures with diameters inferior to 100 nm (Figure 1).3740 By adjusting parameters such as the chemistry of the electrolyte, voltage and current density, one can control physicochemical properties of surfaces,41, 42 and the diameter and the spacing between nanotubes can be precisely modulated.43, 44 In addition, by adjusting the applied potential, it is also possible to transform the protective amorphous oxide layer into one of its crystalline forms.45 On titanium surfaces, anodization also permits to create, through a porous alumina mask, pillar-like nanostructures with tunable sizes as well as to deposit 10 μm-long titania nanotube arrays.46, 47 Nanostructured layers on various metallic surfaces have been similarly created using electrophoretic deposition.36 For example, nanocrystalline hydroxyapatite (nano-HA) coatings (crystals size in the 15–25 nm range) and multi-walled carbon nanotubes have been deposited on titanium-based metals, resulting in an improved bioactivity.48, 49

Figure 1.

Figure 1

SEM images of vertically oriented TiO2 nanotubes of different diameters. Scale bars: 200 nm. Adapted from Reference 41. Copyright 2009, Wiley.

A simple chemical patterning approach using combinations of strong acids (or bases) and oxidants has been shown to efficiently generate networks of nanopits (pit diameter ranging from 20 to 100 nm) on titanium, Ti6Al4V and CrCoMo alloys, and tantalum (Figure 2).50, 51 Surface topography, wettability, micro and nanoroughness, as well as the thickness of the protective oxide layer, can be precisely controlled by adjusting the length of exposure, the temperature and the composition of the etching solutions.5153 In addition, varying the nature of the etching solution makes it possible to incorporate selected elements (e.g. fluorine, which has antibacterial effects54 and contributes to bone formation55) in nanotopographic surfaces created by oxidative treatment.50

Figure 2.

Figure 2

Characteristic SEM images of Ti surfaces nanostructured by oxidative etching with different solutions (scale bar 100 nm). Reproduced with permission from Reference 50. Copyright 2008, ACS.

Anodic oxidation and chemical etching have been combined to create metal/polymer composites with enhanced biological properties. Anodized nanotubular titanium has been coated with NaOH-treated nanoporous poly-lactic-co-glycolic acid (PLGA). The generated nanostructured Ti/PLGA composite stimulated cell activity, but compared to anodized titanium, no significant difference was seen.56 A one-step chemical method based on a combination of NaOH and hydrothermal treatments has also been applied to titanium to create a wide variety of bioactive nanostructures, such as nanoleaves, nanoneedles, nanorods, nanotubes and multi-scale octahedral whiskers (Figure 3).57

Figure 3.

Figure 3

SEM images of the structures formed on titanium metal at 250 °C, 5 h by varying the hexamine to NaOH molar ratio. Transition from nano-needles to nano-rods. Reproduced with permission from Reference 57. Copyright 2010, IOP.

The properties of metallic surfaces can also be modified at the nanometric level by sol–gel chemistry and chemical vapor deposition (CVD), among others.58, 59 Niobium oxide and diamond-like carbon presenting characteristic nanotopographies have been deposited by these techniques on titanium and other substrates, providing additional avenues for improving the bioactivity of implantable metals.6063

A different strategy to improve commonly-used implantable metals is grafting bioactive molecules by simple adsorption or covalent linkage, usually peptides or proteins, to reproduce the biochemical environment that naturally sustains biological processes in the body (reviewed in references 6466). These are usually peptides which regulate cellular adhesion (e.g. RGD-containing peptides) or extracellular matrix (ECM) proteins (e.g. collagen type I, fibronectin, vitronectin, bone sialoprotein) that coordinate the mineralization process.6770 Growth factors such as bone morphogenic proteins (BMPs) and transforming growth factor beta (TGFβ) participate in the recruitment and final osteogenic differentiation of undifferentiated mesenchymal cells.66, 7173 In addition, pectic polysaccharides, a group of molecules normally present in plants, have demonstrated the capacity to activate cell proliferation.74 Chitosan, a molecule generally extracted from crustaceans, has also been used to coat titanium and other metals.75, 76 Coatings with such molecules thus represent additional strategies for improving the biocompatibility of medical devices. The same complexing approach can be exploited to graft antibacterial agents (e.g. lysozyme and/or poly(ethylene glycol)77 and antibiotics,7882 as well as more complex structures such as self-assembled organic helical rosette nanotubes.83, 84

Most works so far have dealt with the simple adsorption of molecules. However, silanes and phosphonates have shown to be very effective spacers to covalently link bioactive proteins and peptides to titanium surfaces.79, 8587 Noteworthy, silanes and phosphonates have the additional capacity to directly affect cellular functions.88, 89

Molecular coatings have not been developed solely to favor and enhance cellular functions. In fact, in addition to antibacterial surfaces, there are other applications where the capacity to prevent adhesion is strongly required. For example, in angioplasty, the adhesion of platelets and uncontrolled cell growth onto the inner surface of cardiovascular stents may potentially result in the obstruction of the vessel. For this reason, biochemical surface coatings composed of non-fouling90, 91 and anticoagulant92 agents have been created to suppress interactions between the metallic surface and the surrounding biological environment. Interestingly, a common protein such as bovine serum albumin (BSA) can be used to control the subsequent adsorption cascade by exploiting its capacity to efficiently block non-specific interactions.93 In the case of cardiovascular stents, biochemical functionalization has been applied to deposit plasmid DNA and self-assembled monolayers (SAMs) that provide drug-eluting capacities.94, 95 Finally, electrodeposition of nanoparticles and their slow-release has recently been reported as an alternative for the targeting cardiovascular malfunctions.96

2.2 Physical methods

A variety of physical methods has been used to generate bioactive nanotopography on metal surfaces. These include plasma97 and physical vapor deposition (PVD).98, 99 In addition, self-assembled nanonodules and nanorough tantalum layers with well-controlled nanoroughness have been deposited on titanium by e-beam physical vapor deposition technology.99, 100

A particular category of physical methods includes technologies which provoke atomic rearrangements, such as ion implantation and thermal oxidation. Approaches based on ion implantation (reviewed in reference 101) offer the possibility to insert selected biologically effective ions (i.e. Ca2+, F, Na+, P+, etc.).102, 103 This technique allows the fine control of the concentration and depth distribution of the implanted elements. However, the potential creation of superficial stresses (removable with a post-annealing)101 and/or modification of preexisting surface nanometric features21 must be carefully considered when using this highly-energetic process. Annealing and/or thermal oxidation have been explored on titanium-based metals to enhance their bioactivity by changing the crystalline structure of the nanometric native oxide layer. Previous studies have in fact compared the different crystalline forms of titanium dioxide, and assessed that rutile enhances cellular response.104, 105 However, the anatase crystalline phase with a superimposed nanometric topography, generated by DC reactive magnetron sputtering, yielded the best biological results, compared to amorphous TiO2 and rutile. 45

3. In vitro protein and cellular studies

3.1 Biological surface science

The scientific rationale behind the application of nanotechnology to biomedical surface science correlates with the capacity of cells to sense and recognize specially designed substrate features. Living cells are composed of various structural and molecular elements, synergistically interconnected in a hierarchical system capable of relating events occurring at different levels (i.e. from the molecular to the micrometric scale) and reacting accordingly. In fact, initial cell-substrate interactions take place at the molecular level, but their effects propagate efficiently throughout the entire structure of the cell, ultimately generating a concerted multiscale cellular response.106 For this reason, the capacity of initiating and controlling cellular reactions at the nanometric level through nanoscale physicochemical cueing translates into the ability to affect and direct the global behavior of the cell.

When a surface is in contact with the biological environment, the first event which takes place prior to protein adsorption and cell colonization is water adsorption (time scale of order of nanoseconds).107 The properties of the surface water shell dictate the following events, i.e. the adsorption of plasma and extracellular matrix proteins, determining their orientation, coverage and potential denaturation.107109 Ultimately, the resulting protein adlayer will act as a framework on which cells can adhere, spread, migrate and proliferate. However, it is still not clear whether the observed cellular effects are solely mediated by the protein adlayer or whether the physical surface can also provide cues.

3.2 In vitro protein-substrate interactions

In vitro studies have revealed that the adsorbed protein layer is sensitive to specific physicochemical properties of the implant surface. Nanometric features are more effective in dictating protein adsorption and ultimately determining the biochemical characteristics of the adlayer.110 Surface structuring at the nanoscale may result in changes in surface area/energy, distribution of functional groups, hydrophilicity and oxide composition/thickness, which have been shown to be critical factors to control protein adsorption.111114 In particular, surface topography is also known to affect protein orientation and denaturation, which play a fundamental role in determining the outcome of the subsequent cell colonization.115117 It is believed that only topographical features with dimensions similar to those of surface-bound proteins (~10 nm) can significantly affect their morphology and activity.110 There have been several studies to determine how proteins respond to nanometric features of diverse sizes and morphologies.115, 118122 These have concluded that the adsorption of proteins such as fibrinogen, albumin, and fibronectin (FN) is generally enhanced by nanorough surfaces, although the effect is not always significant.123 In the case of fibronectin. the vertical dimension of nanometric surface features seems to be critical in determining its adsorption profile. This protein is differentially responsive to the depth of nanometric cavities and to the height of spherical ordered nanostructures, ultimately determining the size of the focal adhesions (FAs) (see section 3.3.3).124, 125

3.3 In vitro cell-substrate interactions

3.3.1 Considerations about cells for in vitro studies

Various in vitro cell models have been used to better understand the effects that nanostructured surfaces exert on cellular reactions. The choice of a specific cell type reflects the biological property under investigation and ultimately, the application envisaged for a material. For instance, osteoblasts (i.e. bone-forming cells) are used to evaluate the capacity of materials to promote bone formation for orthopedic and dental implants. Similarly, fibroblasts (i.e. soft connective tissue-forming cells) have been used to evaluate the ability to promote or limit the growth of fibrous tissues. In addition, endothelial (i.e. vascular lining cells) and smooth muscle cells allow to assess cardiovascular repair potential. Stem cells (i.e. pluripotent undifferentiated cells126) are generally used to determine whether a given nanotopography can induce differentiation along selected pathways.

Cells used for in vitro experiments generally derive from transformed cell lines. Although these cells in large part reflect the activity of the cell type from which they derive, they may not necessarily yield similar bioactivity outcomes. On the other hand, primary cultures with cells isolated from tissues are more difficult to grow, generally loose phenotypic specificity as they are passaged, and exhibit greater biological and differentiation variability. The latter, however, reflects more closely the in vivo healing situation where cells at various stages of differentiation are found.

3.3.2 Cellular response to nanostructured metals

The short-term (i.e. cell adhesion and proliferation) and long-term (i.e. bone matrix secretion and mineralization) functions of osteoblasts can be stimulated by anodized titanium surfaces.40, 62, 127 Such surfaces also sustained the in vitro growth and osteogenic differentiation of human skeletal mesenchymal stem cells (hMSC),47, 128 and also induced cytoskeletal reorganization and increased the frequency and size of FAs (Figure 4).47 Interestingly, the capacity of anodization to precisely control the nanotopographical features permitted to correlate cell function with diameter and spacing of nanotubular structures.44, 129 In particular, nanotubes with 15 nm diameter significantly enhance the adhesion, spreading and differentiation of mesenchymal stem cells as compared to nanotubes with 70–100 nm.44, 130 In addition, a spacing of 15 nm provided an effective length scale for accelerated integrin clustering and FAs formation (see section 3.3.3).44 Other cell types such as chondrocytes (cartilage-forming cells) and keratinocytes (epidermal cells) were shown to better respond to anodized surfaces.131, 132 On the other hand, bacterial growth is significantly limited on nanorough titanium surfaces.133 These results suggest that anodization can be an effective tool for cartilage applications and can be exploited to improve current bone-anchored transcutaneous implants, as well as to endow implantable metals with antibacterial properties.

Figure 4.

Figure 4

Side-view SEM images of Ti surfaces after anodization at three different voltages and chemical removal of the alumina masks (above). Cytoskeletal and FA staining in hMSCs cultured on planar control and nanostructured Ti surfaces (below). Red, actin microfilaments; green, either tubulin microtubules; vimentin intermediate filaments or vinculin; blue, cell nucleus. Cells cultured on 15 nm high structured surfaces display a well-defined cytoskeleton and large focal adhesion sites, whereas on the higher structured surfaces cells have a less organized cytoskeleton and fewer, smaller focal adhesions. Picture adapted from Reference 47. Copyright 2009, Elsevier.

Oxidative nanopatterning confers titanium-based metals the exciting capacity to selectively influence cellular behavior, by favoring the growth of osteoblastic cells while limiting that of fibroblastic ones.21, 52 Very interestingly, adhesion of the two cell types after 1 and 4 hours of treatment was similar on smooth and nanoporous surfaces, suggesting that the effects of the nanotexture do not significantly relate to cell adhesion but rather to cell growth and differentiation. Selective adhesion also takes place on carbon nanofiber compacts (surface roughness of about 0.2 nm as determined by SEM stereoimaging), which have been demonstrated to enhance the osteoblastic activity and limit that of smooth muscle cells, fibroblasts and chondrocytes.134 The physicochemical cueing resulting from oxidative nanopatterning also impacts on gene and protein expression, leading to enhanced osteogenic cell adhesion, spreading and proliferation.5052, 135, 136 The generated nanoporous surface induces an early upregulation of bone sialoprotein (BSP) and osteopontin (OPN) expression and promotes extracellular fibronectin assembly.50, 135, 136 Early enhanced secretion of proteins with cell adhesion capacity and their assembly onto the surface with which cells interact will affect cell dynamics at an early crucial stage when key parameters of tissue healing are decided.137140 In addition, osteogenic cells grown on nanostructured titanium surfaces created by either H2SO4/H2O2 or NH4OH/H2O2 etching exhibit a significant upregulation of genes associated with cell adhesion and migration,50 such as integrin alpha-5 and hyaluronan, as well as an enhanced extracellular fibronectin assembly (Figure 5).50, 136 Similarly to anodization, oxidative nanopatterning can harness the power of stem cells by promoting their growth.50 Importantly, a differential gene expression profile has been detected for hMSCs and osteogenic cells grown on nanopatterned titanium surfaces.50, 141 Also, expression of key bone markers was upregulated, including that of alkaline phosphatase and Runx2.141 These results indicate that anodization and oxidative nanopatterning are likely to have a key impact on regenerative medicine, as a strategy to achieve predictable tissue healing around the implant.

Figure 5.

Figure 5

Epifluorescence of calvarial osteogenic cells grown on control (A–C) and nano Ti (chemically oxidated with H2SO4/H2O2) (D–F) at 3 days, labeled with anti-fibronectin (A,D, green fluorescence) and anti-alfa 5 integrin (B,E, red fluorescence) antibodies. (C,F) Merged pictures of A,B and D,E, respectively, indicating that alfa 5 integrin expression colocalizes with extracellular fibronectin (yellowish). Integrin alfa-5 expression is up-regulated in osteogenic cells grown on nano Ti.50 Blue fluorescence indicates cell nuclei (DAPI DNA stain). Scale bar = 20 μm, (unpublished picture).

Nanostructured bioactive coatings generated by sol-gel and chemical vapor deposition enhance osteoblastic cell adhesion and proliferation.61, 63, 142 Surfaces modified by covalently-bonded bioeffector molecules have the capacity to positively influence in vitro osteogenic functions, mainly cell attachment, adhesion, proliferation and gene expression.64, 143147

Concomitant with these chemical methods, physical approaches confer an enhanced biocompatibility to implantable materials by creating on their surfaces coatings presenting nanoscale features. For example, PVD was applied to create modify titanium surfaces with different nanotopographical coatings on titanium surfaces for in vitro studies aimed at evaluating the effects of surface chemistry and topography on the cellular and/or tissue response.98, 148

The results of in vitro studies are summarized in Table 1.

Table 1.

In vitro results with nanostructured metals.

Metal Method Nanoscale surface features Tunable surface properties Biological outcome Ref.
Titanium, Ti6Al4V Anodization Nanotubes (diameter < 100 nm) Pore size, nanotube length, oxide thickness, crystallinity Enhanced osteogenic activity (adhesion, proliferation, bone matrix secretion and mineralization), promotion of focal adhesions assembly, stimulation of hMSC cell activity (growth and differentiation), enhanced adhesion of chondrocytes and keratinocytes, limitation of bacterial growth 36, 3841, 62, 127, 128, 131133, 239
Titanium, Ti6Al4V, CrCoMo, Tantalum Oxidative nanopatterning Nanoporous structure (20–100 nm diameter) Micro and nanotopographies, oxide thickness, chemical inclusions (F, S) Differential activity (enhancement of osteoblastic activity and limitation of fibroblast growth), gene and protein (BSP, OPN, Alkaline phosphatase, Runx2) upregulation, stimulation of HUC stem cells, antibacterial effect 5053, 135, 136, 141
Titanium Hydrotherma l+NaOH treatment Nanoscaffolds, nanoflowers, nanoleaves, nanoneedles, nanorods, nanotubes and multi-scale octahedral whiskers Dimensions of nanostructures Enhanced protein adsorption 57
Titanium Sol-gel and Chemical vapor deposition (CVD) Nanotopograhical niobium oxide and diamond-like carbon Nanoscale roughness, layer thickness, crystallinity Enhanced osteblast adhesion and proliferation 58, 59, 61, 63, 142
Titanium, Ti6Al4V Biochemical functionalization Molecular coatings (molecules with RGD motifs and ECM proteins, antibacterial agents, antibiotics, nanorosette, non-fouling and anticoagulant agents) Molecular functional groups, coating thickness Enhanced osteoblast attachment, adhesion, proliferation, gene expression, antifouling and anticoagulant properties 38, 64, 67, 68, 7784, 9092, 143, 145, 146
Titanium, Ti6Al4V Plasma deposition, physical and e-beam vapor deposition (PVD), electron-gun evaporation Nanostructured titanium, titanium nitride, zirconium nitride, tantalum coatings Nanoscale roughness, coating thickness Enhanced osteoblast proliferation and Ca deposition, enhanced fibroblast attachment 97100
Titanium Ion implantation Implanted Ca2+, F, Na+, P+, etc Concentration and depth distribution of implanted elements Improved osteoconductivity 101103
Titanium, Ti6Al4V Thermal oxidation/Annealing and DC reactive magnetron sputtering Crystalline TiO2 layers Nanotopography, crystalline structure Improved osteoblast activity, enhanced osteoblast adhesion, spreading, proliferation and differentiation (on anatase) 45, 104, 105

3.3.3 Potential mechanisms for cell adhesion and proliferation at the nanoscale

Cells adhere to and interact with their extracellular environment through focal adhesions (FAs) (Figure 6). These are dynamic clusters - 15–30 nm in dimension149 - of transmembrane proteins called integrins that anchor cells and transmit mechanical and regulatory signals.150 Integrins interact intracellularly with cytoskeletal elements and extracellularly with matrix proteins containing an RGD (arginine-glycine-aspartate) motif. The number of attached cells correlates with the average RGD surface density, and higher RGD surface densities lead to an increase in FA formation.151

Figure 6.

Figure 6

Schematic drawing of focal adhesions (FAs) showing the interactions of Integrin molecules with other proteins on both sides of the lipid bilayer (unpublished picture).

Threshold dimensions of nanostructures relating to the assembly of FAs have been established (reviewed in reference 152). The observed cellular effects on nanostructured substrates may in part relate to the propensity of the cell membrane to stretch towards points of stability and in so doing trigger nanoscale cytoskeletal reorganization. The sum total of these nanoscale deformations at various points along the cell membrane will trigger typical signaling pathways that regulate cell behavior. The mechanisms by which integrins signal into the cell interior are complex and they involve several different pathways, such as the cytoplasmic protein tyrosine kinase, called focal adhesion kinase (FAK).150 Nanoscale pits upregulate FAK signaling in osteoblastic cells.152 Similarly, nanoporous surfaces are believed to significantly affect the activation of GTPase Rho at FAs,152, 153 an enzyme known to play a part in the maturation of the adhesive complex by promoting recruitment of actin filaments and integrins to the contact site.150, 154

During interaction with bi-dimensional substrates the cell changes its shape and dynamically develops extensions called lamellipodia (membrane veils rich in actin) and filopodia (finger-like protrusions) that act as sensing and traction elements to allow cells to crawl and perceive topographical cues.151, 153 Nanotopography promotes the formation of these membrane specializations (Figure 7). Changes in cell shape are as influential as signaling molecules in the differentiation process.155159 Indeed, it has been shown that cell shape regulates the switch in commitment of stem cells towards an osteoblastic phenotype by modulating endogenous RhoA activity.160

Figure 7.

Figure 7

SEM-Micrographs displaying 3T3-fibroblast adhering to micro-nanopatterns (A and B) and to an extended nanopattern (C). The dot spacing was 58 nm in all samples. Reproduced with permission from Reference 153. Copyright 2007, RSC. Filopodia of primary calvarian cells sensing the nanotexture generated on titanium by oxidative nanopatterning (D–E)135 (unpublished picture).

4. In vivo and clinical applications

4.1 In vivo response of nanostructured implants

Significant efforts have been made so far to integrate surface modification approaches with implant manufacturing in order to ensure superior clinical performance of current prostheses.161163 In this context, while the mechanical performance of a device is mainly defined by its macroscopic shape, tissue integration and long-term stability result from the interactions between the implant surface and the surrounding biological environment at the cellular and molecular level.164167 Based on the in vitro results, nanostructured metals undoubtedly have the potential to yield a faster and more stable integration of biomedical implants.34, 56 To validate this hypothesis, several nanoscale surface modification approaches are currently under investigation to determine their effects in vivo and their potential applicability to commercial implants.34, 168170 Here, we present an overview of methods that have been successfully adapted to nanomodify metallic implants and the resulting animal and clinical outcomes. The results of the in vivo studies are summarized in Table 2.

Table 2.

In vivo results with nanostructured metals.

Metal/Implant Method Nanoscale surface features Surface chemistry (Doping) Surgical protocol Biological outcome Ref.
Titanium rod Anodization TiO2 nanotubes (30 nm diameter) N/A Pig frontal skull - 3, 7, 14, 30, 90 days Stimulation of collagen-I expression 168
Titanium screw, rod Electrochemical deposition, Promimic HANano© HA nanocrystals Ca, P Rabbit proximal tibia – 4, 6, 12 weeks; Improved bone- to-implant contact, early bone formation 172, 173
Titanium screw Micro-arc oxidation (MAO) N/A Mg Rabbit Tibia – 3, 6 weeks Improved bone- integration and removal torque 175178
Titanium screw Oxidative nanopatterning Nanopores (20–25 nm diameter) N/A Dog mandible – 3, 8 weeks Improved bone- to-implant contact 179
Titanium rod, screw TiO2 blasting+HF acid treatment Uncharacterized features (50–200 nm in size) F Rat tibia – 21 days; Dog mandible – 2 weeks Stimulation of osteoblastic gene expression, enhanced bone formation and bone-implant fixation, good osteointegration and stability after 1 year 55, 180183, 185
Titanium rectangular plates, rod, Dual acid etching (DAE)+Discrete crystalline deposition (DCD) CaP nanocrystals (20–100 nm in size) and nanoparticles N/A Rat femur – 9 days; Human posterior maxilla – 4, 8 weeks, 2 months; Dog tooth socket - 4 h, 1, 2, 4 and 8 weeks Improved bone- to-implant contact and bone formation, enhanced tissue mineralization, less bone desorption 186189
Titanium rod Ion beam assisted deposition (IBAD) Nano-thick (20–500 nm) bioactive (Ca- and P-based) ceramic layers Ca, P Dog proximal tibia – 2, 4 weeks Improved fixation 190, 191
Titanium screw Hydrothermal alkaline treatment Uncharacterized features (about 100 nm in size) Ca Rabbit femur –6 weeks; Improved bone- to-implant contact and removal torque, enhanced osteoconductivity 171, 192194
Titanium screw Bioceramic grit-blasting (BGB)+Acid Etching (AA) Nanorough topography Ca, P Dog tibia – 2, 4 weeks, 2 months Early biomechanical fixation and improved bone- to-implant contact 195, 196

A recent study has exploited controlled anodization to endow the surface of titanium implants with self-organized and highly ordered TiO2 nanotubes (30 nm diameter). Implanted in the frontal skull of pigs, these nanotubular surfaces stimulated collagen type-I expression by osteoblasts.168 However, no significant difference in the amount of peri-implant bone formation was observed, suggesting that these nanotubular surfaces ultimately have no impact on osseointegration. These results differ from previous in vitro40 and in vivo171 studies with similarly treated surfaces but different nanotube diameters (i. e. 70–80 nm and 250–800 nm diameter nanotubes, respectively). These concluded that anodized titanium does not impact on the total collagen content but enhances peri-implant bone formation.40, 171 Such differences may result from various factors related to the material properties, such as the different surface topography (i. e. nanotube diameter), degree of crystallinity of the titanium dioxide overlayer, or to other factors unique to in vivo studies, such as surgical considerations (see discussion). Consistent with the results previously described (see section 2.1), anodic oxidation also allows deposition of nano-hydroxyapatite (nano-HA) coatings (Figure 8).172 Histomorphometric evaluation showed that nano-HA modified implants have significantly greater bone-to-implant contact (BIC) values compared to acid-treated implants. The enhancement of BIC by hydroxyapatite nanocrystals was confirmed in a different study in which it was also shown that early bone formation depends on the size and diameter of the nanosized hydroxyapatite crystals.173 The same research group exploited a sol-gel technique to deposit nanotopographic titanium dioxide coatings that also enhanced BIC.174

Figure 8.

Figure 8

SEM micrograph of the CaP rodlike crystals. Reproduced with permission from Reference 172. Copyright 2009, Elsevier.

Micro-arc oxidation (MAO) has been used to dope the implant surface with magnesium.175, 176 Although this technique does not result in topographical modifications at the nanoscale, the presence of Mg ions yielded a more rapid and stronger bone-integration, as well as higher removal torques than commercial microrough highly-crystalline and phosphate-enriched titanium implants.177, 178

Oxidative nanopatterning with H2SO4/H2O2 creates nanotopography on bulk metals,50 as well as on titanium screw-shaped implants (Figure 9). Oxidative treatment of commercial screw-shaped titanium implants placed in dog mandibles resulted in enhanced BIC values and osteogenesis and this even though no nanotexture was obtained.179 The authors suggested as an explanation that the passivation of the implant generated chemical conditions affecting the dynamics of the deoxidation/reoxidation processes. This study, however, shows that existing commercial implants can be significantly improved using a simple treatment that does not require elaborate changes in manufacturing.

Figure 9.

Figure 9

Nanoporous surface (A) generated on miniature (1.0 mm inner diameter; 1.5 mm outer diameter; 2.4 mm head diameter; 0.4 mm head thickness; 1.6 mm implant length) Ti6Al4V screw-shaped implants (B) (Med Machining Inc, Miami Lakes, FL) by oxidative nanopatterning (unpublished picture).

The combination of TiO2 blasting and hydrofluoric acid treatment has been used to create a commercial endosseous titanium implant with microrough surfaces with superimposed uncharacterized features ranging between 50 and 200 nm.180 These implants stimulated osteoblastic gene expression, as well as they enhanced bone formation, osseointegration and bone-implant fixation.181183 While some inflammatory response was reported,184 the overall success rate was satisfactory, with the majority of implants yielding good osseointegration and stability after one year post-surgery. Noteworthy, high success rate was also reported under more challenging clinical conditions such as early loading.185

Dual-acid-etching (DAE) followed by discrete-crystalline-deposition (DCD) has been used to create calcium phosphate (CaP) nanocrystals (20–100 nm in size) coated titanium implants.186 These implants were clinically evaluated in a randomized controlled trial (RCT), which concluded that BIC in the posterior maxilla increased by about 12%.187 In addition, bone formation around CaP nanocrystal-coated implants was enhanced.188 The observed capacity to accelerate bone formation is expected to result in a faster healing response which ultimately may permit earlier loadings. A recent study in dogs comparing bone formation around DAE and CaP nanocrystals-coated implants showed that there was no statistical difference in BIC in the early healing phase (1–4 weeks).189 However, test sites containing implants coated with nanoparticles exhibited less bone resorption.

Another commercial implant, which was however discontinued in 2009, was produced by ion-beam-assisted-deposition (IBAD) of thin (20–500 nm) bioactive Ca- and P-based ceramic layers.190 With a 300–500 nm thick coating, the BIC value was not significantly affected, but the implants presented higher torque-to-interface fracture levels compared to controls, indicating an improved fixation.191. However, the biomechanical properties degraded when the bioactive layer thickness was reduced to 20–50 nm and there was no improvement of BIC values and bone fixation at early implantation times (2 and 4 weeks).190 This outcome was partially attributed to the reduced thickness and to the amorphous microstructure of the deposited material, which may have caused its rapid dissolution.

Nanostructured surfaces presenting uncharacterized features of approximately 100 nm have been obtained on microrough titanium implants by hydrothermal alkaline treatment.192 This method also caused incorporation of calcium as CaTiO3 in the protective surface oxide layer. Titanium and Ti6Al4V implants with thus treated surfaces significantly increased BIC and removal torque forces in rabbit tibiae.171, 193, 194 In addition, this treatment improved bone formation around implants placed in trabecular bone.192

Bioceramic grit-blasting and acid etching (BGB/AA) technologies have been integrated to produce submictrometric topography on titanium implants.195 Histological evaluation after 2 months post-surgery showed significantly higher BIC and osteocyte density around modified implants when compared to dual acid-etched implants.196

4.2. Antibacterial and cardiovascular implants

Infection at the implantation site represents an important clinical complication. In the United States, approximately 4.3% of the orthopedic implants developed bacterial infection. In the case of cardiovascular devices, the annual infection rate is even higher (7.4%).197 Coatings deposited by chemical (e.g. wet-chemistry approaches) and physical (e.g. PVD) processes (reviewed in reference 198) have been successfully applied to control bacterial colonization of implanted prostheses. For example, biodegradable gentamicin-loaded poly(d, l-lactide) (PDLLA) coatings prevented implant-related osteomyelitis (i.e. infection of bone) around titanium wires.199

In this context, while titanium-based metals are the most common material for dental and orthopedic applications, their use in cardiology is still limited.200 Stainless steels, Ni-Ti (Nitinol) and Co-Cr alloys, as well as Tantalum, are in fact more often encountered in cardiovascular applications.200 Degradable magnesium- and iron-based alloys are also now being considered in cases when the implant is only temporarily needed, such as for stents.12, 13

Stents capable of slowly releasing drugs (i.e. immunosuppressant, chemotherapeutic, etc), for example to block cell proliferation or prevent the formation of scar tissue at the site of coronary intervention, are already approved and commercially-available (drug-eluting stents, DES).201 However, the polymeric coating used in DES may be cause short-term inflammation as well as long-term thrombotic events.202 Nanostructured may represent an alternative such polymer-based DES. In this context, nanoporous surfaces generated on coronary stents by various techniques yielded promising results in terms of drug-eluting capacities (reviewed in reference 202) (Figure 10). For example, a nanostructured stent was developed by coating a 316L stainless steel with electrochemically-generated nanoporous Al2O3.203 However, the clinical performance of this system was not satisfactory.204 In addition, nanoporous metallic coatings were created through sputtering techniques, which allow deposition of a variety of materials, including cobalt chromium, nitinol, platinum, and stainless steel.202 Oxidative nanopatterning has also been efficiently applied to sputtered titanium to create a network of nanopores.122 Therefore, deposition of thin films of titanium on substrates that are not readily amenable to chemical oxidation could be advantageously exploited to create nanotextures offering antiadhesive properties,50 thus providing a valuable strategy to improve the integration of stents made of different metals.

Figure 10.

Figure 10

A nanoporous stent surface: a scanning electron microscopic view of a Setagon stent (x 20,000). Stent struts are gilded with this nanoporous layer (estimated porosity of 30%), which functions as a reservoir for prolonged release of antirestenotic drugs. Reproduced with permission from Reference 202. Copyright 2007, Informa Healthcare.

4.3. Micromotion and nanotopography

The primary stability of an implant results from the biomechanical interlocking of the implant and the surrounding bone. In addition to implant-related factors (material, design, topography and surface chemistry), surgical procedure and patient variable (bone quantity and quality, health condition),205 the local mechanical environment has been recognized as a critical factor for bone repair and regeneration around an implant.206 However, the exact biomechanical parameters involved in the initial healing process at the tissue-implant interface remain elusive. Several studies have demonstrated that micromotion during implant loading, can arise from various factors including: (1) the physical properties of the bone tissue (e.g. elastic moduli of adjacent bone and strength of attachment between implant and tissue), (2) the mechanical interaction between the implant and tissue, (3) the initial fit of the implant in the site, (4) the geometry of the implant,207209 and of course (5) the characteristics of the loading.206, 208 Depending on the magnitude and direction of resulting micromotion at the interface, tissue differentiation around immediately loaded implants can respond differently; excessive micromotion may be a compromising factor that leads to interfacial fibrous tissue formation and prevention of osseointegration, while at the lower range, there is evidence that there may be positive effects on bone repair and regeneration.210215 Overall, the exact dynamics of the interfacial events that lead to osseointegration when healing occurs under loading and the limits of relative motion as well as the specific aspects of micromotion that actually cause problems at the bone-implant interface still have to be established.

Implant micromotion per se may not be the decisive factor in interfacial healing; instead, there is now evidence that the motion-associated interfacial principal strain magnitude – along with its spatial distribution, duty cycle, waveform, etc. – is the factor that most influences osseointegration.216, 217 This is a significant finding because of the current debates surrounding ‘immediate’ vs. ‘delayed’ loading of implants218, recall that implant loading inevitably creates strain fields at the interface, whether the loading starts immediately after implantation, or later, after the bone has had a chance to heal to some degree. Therefore, as one contemplates strategies for the design and use of dental and orthopedic implants, it is not the timing of loading that is the primary issue, but rather the propensity of the implant to undergo micromotion and thereby create strain in the local interfacial. Although previous studies have tried to derive a single value of limiting strain and stress levels beyond which bone regeneration is compromised,206, 219 it may not be possible to define such a value, even the exact type of stress or strain that is key is also unclear. It is well to remember that continuum-based models of mechanotransduction will always have limitations when it comes to unraveling detailed molecular-level mechanisms at the cell level, as elegantly discussed by Humphrey.220 However, based on ongoing studies on a mouse tibial model, it has been estimated that ~30% principal strain (tensile or compressive) represented an upper limit to allowable principal strain magnitude during interfacial bone healing.217, 221 There are also orthopedic studies from the fracture healing and dynamization literature that also support this view, although again, exact thresholds remain elusive.222224 Since an appreciable number of implant losses have been considered to possibly be the result of excessive strains and stresses at the bone-implant interface, a better knowledge of the interfacial stress-strain conditions that are tolerable as opposed to deleterious interfacial stress-strain conditions is essential, and would lead to understanding the mechanically-controlled tissue differentiation process, that is the “mechanobiology” at the interface.

On question that has received relatively less attention is whether surface characteristics have an impact on the interfacial mechanobiology. This aspect should be considered at multiscale levels, including the macro, micro and even the nano levels. Macro- and micron-scale surface modifications have been exploited for some years now to create biomechanical environments that can significantly modulate tissue healing around bone implants. For example, there is a long history of exploring “optimal” porous implant designs for bony ingrowth as well as attempts to understand the role of surface roughness at the micron-scale in terms of implant accommodation in bone.225 The more recent recognition that interactions between biomaterials and host tissues also take place on the nanoscale has focused attention of researchers and industry to a new generation of implantable metals with nanoengineered surfaces. This has in part been driven by intriguing work suggesting that an implant’s surface texture or roughness may alter cell shape and cytoskeleton, which in turn may influence gene expression.226229

As a consequence, there is already a growing body of literature exploring the role of nano-level mechanics on cell-substrate interactions as well as cell-cell interactions. For example, recent reviews indicate that substrate elasticity as well as mechanical deformations (strain) of cells play a role in determining stem cell fate decisions.106, 230 This latter perspective naturally leads to the idea that the nano-level mechanical properties of an implanted biomaterial could be influential in determining cell fate decisions adjacent to a biomaterial. As stated by Discher et al. “… not only physical contributions to differentiation but also that carefully made materials can help prime the expansion of specific progenitors.”230 Finally, this last perspective also leads to the notion that finite element analyses and similar mechanical modeling methods could help take account of the truly multiscale character of the biomechanics problem at bone-implant interfaces; such models could be helpful to fully scope out the possible interplay of cell deformations in relation to implant surface topography.106

Given this body of work indicating that physical factors at the tissue and cell levels, including roughness, mechanical properties, as well as related stresses and strains, are ultimately transferred to single cells in some manner, it is clear that local strain fields at the macroscale will then affect cellular events at the micron- and nano- (molecular) scale.231 Yet from both mechanistic and implant-design viewpoints, there is little to bridge the gap between implant design at macro- and micron-levels vs. biological mechanisms at the nanoscale. Hence it can be hypothesized that local deformation in healing tissue (e.g. by micromotion) generates changes in the biomechanical relationships between tissue and implant at multiple size scales (macro, micro and nano) and therefore influences local cellular (e.g., cell morphology) and molecular (e.g. gene expression) events. In turn, surface features on the implant may also participate in creating strain fields that regulate cell fate decisions at the bone-implant interface. In fact, a series of nanoscale cell distortions might cumulatively create substantial strain to trigger changes in cytoskeletal organization and activation of different signaling pathways in diverse cell types.232 Since nanoscale topography and chemistry have been demonstrated in vitro to influence the mechanical properties of cells,233, 234 it seems likely that this could be advantageously exploited in vivo to allow the design of an implant that might counterbalance negative effects of ‘excessive’ micromotion. For example, nanoscale cell distortions induced by micromotion could be exploited to selectively trigger cell fate decisions (e.g. osteogenic vs. fibroblastic pathway)232 thereby minimizing fibrous tissue formation and promoting bone formation around loaded implants.

4.4. Considerations on the biocompatibility and cytotoxicity of implantable metals

The cytotoxicity of implanted metals is a major concern in the biomedical field and still object of debate.235 Ions and/or debris released from an implanted material can in fact provoke adverse immune and inflammatory reactions that can ultimately defeat the purpose of the biomedical device. It is commonly accepted that titanium and its alloys are biocompatible. However, some titanium alloys show a certain degree of cytotoxicity due to the alloying elements.236 For example, Al and V were associated to adverse reactions in tissues and neurological disorders.237 In addition, high levels of Cr, Ni and Co raise the risk of carcinogenicity.236 While these effects are known, it is important to point out that the links between a precise concentration of metallic ions and adverse phenomena such as DNA damage, DNA mutation, carcinogenicity and metal sensitivity have not yet been unequivocally established,235 and further studies are thus required.

5. Outlook and perspectives

In this paper, we have presented an overview of current nanotechnology-based strategies (chemical, biochemical and physical) which have been used to improve the in vitro biological response to implantable metals, and in some cases have also shown enhanced in vivo experimental outcomes and found commercial applications. In general, while it can be concluded that nanoscale surface modification introduces novel bioactive capacity into the arena of metallic biomaterials, many of the modification approaches described in this review still remain to be tested in vivo and few have actually been exported to the medical device industry. There are in fact comparatively very few structured animal and clinical studies that investigated the short and especially long-term effects of such surfaces, evaluating whether the enhanced biological activities demonstrated in vitro actually translate to the complex in vivo environment. However, even though it is well known in biology that in vitro conditions do not fully reflect the in vivo reality, such studies are nonetheless essential to screen potentially successful treatments for subsequent animal validation.

From the material point of view, it should be noted that most in vitro studies aimed at probing in detail how cells respond to a given nanostructured substrate have been carried out on non-metallic materials, generally characterized by nanoscale protrusions created by techniques such as colloidal and electron beam lithography, and polymer phase separation.152 There are comparatively few studies that have investigated pits which fit the commonly-accepted nanometric definition (i.e. with dimension smaller than 100 nm),125, 238 on implantable metals. While studies carried out with laboratory materials are undoubtedly important to understand the dynamics involved in cell adhesion to substrates, the resulting cell behaviors may ultimately differ from those on medically-relevant metals which exhibit different surface physicochemical parameters. In this context, anodic oxidation and chemical nanopatterning are efficient tools to create networks of nanometric pits (less than 100 nm in diameter) on implantable metals to probe cell adhesion.47, 50, 135, 239

Since in most cases cell cultures on nanopatterned materials and, as a matter of fact even on microstructured surfaces, are carried out in the presence of proteins, one important question that remains to be addressed is whether there is a direct contribution by surface modification. It is now well established that proteins rapidly form an adsorbed layer on biomaterial surfaces, and that these proteins affect diverse cellular events at the interface, including cell morphology, growth, and function.107109 It is therefore not clear whether the resulting in vitro effects are due to direct signaling by the nanometric surfaces cues, to the protein adlayer or the synergistic combination of these two factors. It can, in any case, ultimately be argued that the cellular outcomes result from the nanometric surface features since these significantly affect protein morphology and activity.107, 118121 Irrespectively, there is another important consideration that needs to be made when translating in vivo protein adsorption profiles to the body. The identity of the first proteins to adsorb onto the surface and subsequent protein-protein interactions may not be precisely predicted due to the complexity, variability and dynamism of the biological environment. In multi-component solutions such as bodily fluids, competitive adsorption and protein displacement concur in determining the final adsorption profile.240, 241 For instance, with time high-molecular weight proteins can displace smaller proteins already adsorbed onto a substrate. Therefore, one would expect that overall a multi-component mixture will interact in a semi-stochastic manner with the substrate, inducing a certain degree of variability in the overall adsorption profile. In addition, in the body at sites where there is bleeding, a fibrinogen coagulate will form rapidly and may partially or completely mask the surface thereby complicating further the formation of an adlayer on an implant.242 One must be therefore extremely careful in extrapolating data obtained in vitro to the reality of the biological environment where the behavior of a protein will not only depend on its physicochemical properties and those of the biomaterial surface, but will also reflect modulation of their behavior by the various tissue and body fluid components it is exposed to.243 Predictable adsorption may ultimately require more selective approaches such as nanopatterning of surfaces with molecular arrays that will determine interactions of the substrate with selected proteins.

There are additional variables determining the final outcome of an implant, such as the implantation site and the overall health condition of the patient. Longitudinal and descriptive human studies, as well as histological data, have indicated that early osseointegration and clinical success rates for endosseous implants vary according to the anatomic location.244 A high success rate has been reported for implants placed in regions with dense bone such as the mandible,245, 246 whereas placement in the maxilla can yield insufficient osseointegration, partially related to poorer bone quality at this site.247 Difficulty in achieving short- and long- term integration and stability of dental implants has also been observed in selected patient populations, such as smokers and diabetics.248, 249 Due to the complexity of the clinical scenario, new nanotextured implants may not necessarily yield the expected outcome when used clinically and longer evaluation periods may be required.250 As stated by Albrektsson, “novel implant systems or moderate/major changes of existing implants need to be clinically tested preferably before clinical introduction, not afterwards”.251 While clearly caution is needed, the animal and clinical studies carried out so far suggest that nanoscale surface modification of metallic implants has a promising clinical future.

A particular problem is that implant studies seldom provide a detailed characterization of surfaces at the nanoscale.252 As stated by Wennerberg, measurements and evaluation techniques need to be standardized.253 For example, roughness measurements as well as protocols to determine surface wettability should be more uniform in order to provide the consistent data that is required for reliable comparison of different implants.254 In this context, contact angle measurements have been extensively used to determine the wettability and free energy of nanostructured substrates53, 255 and characterize biomedical implants, since these parameters affect the interactions between a material and the surrounding biological environment.256259 Experimental conditions (e.g. drop size and symmetry, vibration of the substrate), as well as the physicochemical properties of the substrate (e.g. surface roughness, porosity, chemical homogeneity and presence of adsorbates) and the presence of surface nanostructures, are all factors that influence the overall wettability of a material, and should therefore be carefully taken into consideration during data analysis.258260 In addition, some prosthetic devices commercially-advertised as nanostructured are characterized by inhomogeneous nanofeatures which lack statistical distribution and/or precise reproducibility. In this context, even smooth implant surfaces could be considered nanostructured since they could actually exhibit a nanoscale roughness or some kind of nanometric features. These are, most of the times, the direct consequence of the fact that materials are not naturally atomically flat and characterized by defects. Therefore, the need of a distinction between engineered nanostructures and the native topography of materials at the nanoscale, is legitimate. All these factors may introduce additional variables which, in addition to biological variability, may ultimately confound assessment of the precise role of nanometric surfaces in controlling biological events in living systems. It will be therefore important to optimize current and future nanotechnology approaches to generate surfaces with controlled and uniform surface nanofeatures in order to achieve a better understanding of material/host tissue interactions.

While the majority of studies with nanostructured metals has focused on dental and orthopedic implants, the benefits of nanoscale surface modifications for cardiovascular applications have just started to be assessed.130, 261, 262 A problem associated with current drug-eluting stents (DESs) is the potential cracking/detachment of the polymeric coating during balloon expansion.263 In addition, delayed healing and hypersensitivity reaction to DES polymeric components have been reported.264 Direct nanoscale modification of surfaces without deposition of polymeric overlayers could represent an effective strategy to limit adverse reactions to metallic stents. As an example, porous surfaces capable of selectively influencing cell growth (e.g. chemically-generated nanoporous surfaces50) could improve the performance of existing stents by hampering undesired cell adhesion and proliferation, and also improve tissue healing by synergistic drug release (see below).

Nanostructured materials are extensively used as biologically active molecule-delivering systems.265 Compared to surfaces with nano-protrusions, nanoporous surfaces are very attractive because they 1) offer an increased surface area which translates into a greater surface reactivity, and 2) provide nanoconfined volumes which are expected to modulate dissolution rates. The fact that higher area-to-volume ratios translate into a higher amount of surface reactive sites is well known in physical chemistry and biology, since it determines, for instance, catalytic reaction rates and extracellular substance exchange, among others. On the other hand, nanoconfined volumes influence physicochemical events such as fluid mobility.266 Taken together, these factors indicate that nanoporous surfaces have the potential for enhanced loading ability and the capacity to provide controlled dissolution rates over time.

The greater surface area provided by nanopores can be synergistically exploited to link more efficiently bioactive molecules to metals, with or without the use of intermediate linking agents such as oxyilanes and phosphonates.267 To this end, it will be interesting to compare the outcome of smooth and nanostructured surfaces with covalently-linked synthetic peptides known to promote cell adhesion and osteoblastic differentiation such as (1) the noncollagen-derived RGD,268, and (2) the collagen-derived P-15,269 DGEA270 and GFOGER271 collagen-related cell binding peptides. However, the best linking agents for bioeffector molecules are likely to be more complex molecules, capable of forming multiple stable covalent links (e.g. multidentate molecules) onto metallic surfaces while creating lateral self-assembly. This is also expected to result in the capacity of generating various molecular patterns, with tunable properties (such as the pattern geometry, nature and orientation of active groups), even on surfaces which are not flat at the atomic scale (such as those of commercially-available implantable metals). In this way, it will be possible to extend the panoply of tailored nanostructures by designing organic patterns otherwise non-easily achievable by direct physicochemical methods. In addition, we can envisage molecular arrays capable of responding to specific variations of the surrounding biological environment, such as local changes in the pH or temperature at the material-host tissue interface, paving the way for novel biomaterials.

We believe that future generations of implants should aim at “intelligent” surfaces, capable not only of providing cues to the surrounding tissues but also of receiving and responding to events occurring in them. Here, we anticipate that synergistic approaches will be critical to achieve the challenging goal of endowing implantable materials with the capacity to “dialogue” with the surrounding environment. For example, nanoporous surfaces could be further functionalized with molecular arrays or multi-layered coatings that would in a first step provide signaling to cells and that could in-time respond to local changes in the environment, exposing underlying nanopatterns capable of physical cueing or drug release. It could be conceived that molecular reorganization could also be initiated by external stimuli, such as infrared light, ultrasounds and magnetic fields, for instance. Similarly, functionalized nanoparticles could be embedded in molecular arrays sensitive to local chemical variations.

There is also limited information on whether the release of toxic metallic ions can be limited by nanoengineered surfaces. For example, chemical treatments that, besides generating nanoscale cues, yield an increase in the protective oxide layer could be a possible solution to better ‘insulate’ metals from the surrounding biological environment. In addition, it will be interesting to determine whether surface nanostructures can by themselves altering the dynamics of dissolution and thus reduce cytotoxic effects. This could be the case for nanoconfined volumes such as nanotubes and nanopororosity, coatings with HA nanocrystals, and functionalization with molecular arrays.

A major challenge in regenerative medicine is the capacity to attract local stem cells and to induce their proliferation and differentiation. Physicochemical surface characteristics may offer an interesting strategy to achieve such a capacity around implantable metals and other biomaterials. In addition, biochemical functionalization could be an efficient complement to physical cueing. In this context, in vitro studies have already shown that nanoscale surface cueing can stimulate stem cell growth and guide their differentiation without exposure to molecular signals.50, 272 Although this aspect is just beginning to be explored and still lacks in vivo validation, current results are certainly promising for skeletal applications. An exciting new development in biology is the finding that stem cells can also be obtained from skin.273 Bone reconstruction around an implant could thus be induced by exploiting the ability of nanostructured surfaces to activate stem cells and to accelerate bone formation while avoiding tissue encapsulation.51, 52, 274 This will translate into faster healing and improved stability of dental and orthopedic prostheses, critical aspects especially in aging patients with poor bone support.

In conclusion, nanoscale surface modification approaches are likely to foster profound changes in the ways implants and other biomaterials are designed and manufactured. The application of medical prostheses to improve health and even save lives will continue to grow until tissue engineering reaches a mature level and regeneration of complete tissues can be achieved. Therefore, any procedure that can improve the performance of implantable biomaterials will have a major impact on the quality of life and result in a major economic benefits to society. Advances in metallurgical and surface-engineering techniques, and nanotechnology promise a new generation of improved prosthetic devices with selective bioactive surfaces, and eventually with “intelligent surfaces” capable of responding to the implantation site environment.

Acknowledgments

A. N. acknowledges funding from the Canada Foundation for Innovation and a Collaborative Health Research Project grant funded jointly by the Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC), and separate funding from the CIHR. AN and JB are also recipients of National Institute of Health (NIH) funding 2R01 EB000504-08. PTO acknowledges support from the State of São Paulo Research Foundation (FAPESP) and the National Council of Scientific and Technological Development (CNPq).

Biographies

graphic file with name nihms293771b1.gifDr. Fabio Variola received his B. Eng. and M. Eng. in Materials Engineering from the University of Trieste (Italy) in 2004. In 2009, he completed a joint doctoral program in Materials Science at Institut National de la Recherche Scientifique-Énergie, Matériaux et Télécommunications (INRS-ÉMT) and Université of Montréal. He then carried out postdoctoral training at the Laboratory for the Study of Calcified Tissues and Biomaterials (Université of Montréal). In July 2010, he joined the Department of Mechanical Engineering at the University of Ottawa as Assistant Professor. His research interests focus on surface nanoengineering of biomaterials.

graphic file with name nihms293771b2.gifDr. John B. Brunski has a Ph.D. in Metallurgy & Materials Science (1977) from the University of Pennsylvania. He is currently Senior Research Engineer, Division of Plastic & Reconstructive Surgery, School of Medicine, Stanford University. Previously he was Professor in the Department of Biomedical Engineering, Rensselaer Polytechnic Institute (Troy NY). Among other awards, he received the 2006 Jerome M. and Dorothy Schweitzer Research Award (Greater New York Academy of Prosthodontics) and the 2008 Astra Tech Scientific Award for Applied Research in Osseointegration. His research focuses on dental implant design and interfacial bone biology.

graphic file with name nihms293771b3.gifDr. Giovanna Orsini obtained her degree in dentistry at the University of L’Aquila (Italy) in 1994. After a Certification in Esthetic Dentistry (UCLA, USA), in 2000 she received a M.Sc. in Biomedical Sciences from the Université de Montréal (Canada). In 2005, Dr. Orsini completed a Ph.D. in Stomatology and Oral Sciences from the University of Chieti-Pescara (Italy). She is now Lecturer at the Polytechnic University of Marche (Italy). Her research interests focus on clinical trials, oral calcified tissues, dental biomaterials, and tissue engineering.

graphic file with name nihms293771b4.gifDr. Paulo Tambasco de Oliveira graduated from the Faculty of Dentistry of the University of São Paulo at Ribeirão Preto (Brazil) in 1987 and received his Ph.D. in Oral Pathology in 1997. In 2001 he joined the Laboratory for the Study of Calcified Tissues and Biomaterials (Université de Montréal) for postdoctoral studies. Since 1991 he is Professor of Oral Histology at the University of São Paulo. His current research interest focuses on the study of osteogenic differentiation on metallic and glass-based materials with nanostructured and functionalized surfaces for dental and orthopaedic applications.

graphic file with name nihms293771b5.gifDr. Rima Wazen received her Ph.D. (2006) in Biomedical Sciences from the Université de Montréal (Canada). She is now working as a research assistant at the Laboratory for the Study of Calcified Tissues and Biomaterials at Faculty of Dentistry(Université de Montréal). Her research focuses on the study of cell biology of calcified tissues and tissue integration of biomaterials.

graphic file with name nihms293771b6.gifDr. Antonio Nanci received his Ph.D. in Anatomy and Cell biology from McGill University in 1982 and was a postdoctoral fellow in Craniofacial Molecular Biology at University of Southern California. He is now Professor of Cell Biology and Director of the Department of Stomatology of Université de Montréal. He is also Director of the Laboratory for the Study of Calcified Tissues and Biomaterials, and member of the Scientific Board of the Rizzoli Orthopedic Hospital in Bologna (Italy). His research focuses on the study of basic cell biological processes in normal and pathological calcified tissues and on surface nanoengineering and nanomedicine.

References

  • 1.Kurtz S, Ong K, Lau E, Mowat F, Halpern M. J Bone Joint Surg Am. 2007;89:780. doi: 10.2106/JBJS.F.00222. [DOI] [PubMed] [Google Scholar]
  • 2.Hodgson JM, Bottner RK, Klein LW, Walpole HT, Cohen DJ, Cutlip DE, Fenninger RB, Firth BG, Greenberg D, Kalisky I, Meskan T, Powell W, Stone GW, Zito JP, Clark MA. Catheter Cardiovasc Interv. 2004;62:1. doi: 10.1002/ccd.20025. [DOI] [PubMed] [Google Scholar]
  • 3.Kereiakes DJ, Choo JK, Young JJ, Broderick TM. Rev Cardiovasc Med. 2004;5:9. [PubMed] [Google Scholar]
  • 4.Wong JY, Bronzino JD. Biomaterials. CRC Press; Boca Raton USA: 2007. [Google Scholar]
  • 5.Ratner BD, Hoffman AS, Schoen FJ, Lemons JE. Biomaterials Science: An Introduction to Materials in Medicine. Elsevier Academic Press; San Diego USA: 2004. [Google Scholar]
  • 6.Brown SA, Lemons JE. Medical Applications of Titanium and Its Alloys: The material and biological issues. West Conshohocken USA: 1996. [Google Scholar]
  • 7.Mani G, Feldman MD, Patel D, Agrawal CM. Biomaterials. 2007;28:1689. doi: 10.1016/j.biomaterials.2006.11.042. [DOI] [PubMed] [Google Scholar]
  • 8.Bhat SV. Biomaterials. London UK: 2002. [Google Scholar]
  • 9.Black J. Orthopedic biomaterials in research, practise. Livingstone; New York: 1998. Corrosion, degradation. [Google Scholar]
  • 10.Bobyn JD, Stackpool GJ, Hacking SA, Tanzer M, Krygier JJ. J Bone Joint Surg B. 1999;81:907. doi: 10.1302/0301-620x.81b5.9283. [DOI] [PubMed] [Google Scholar]
  • 11.Witte F. Acta Biomater. 2010;6:1680. doi: 10.1016/j.actbio.2010.02.028. [DOI] [PubMed] [Google Scholar]
  • 12.Purnama A, Hermawan H, Couet J, Mantovani D. Acta Biomat. 2010;6:1800. doi: 10.1016/j.actbio.2010.02.027. [DOI] [PubMed] [Google Scholar]
  • 13.Hermawan H, Dubé D, Mantovani D. Acta Biomater. 2010;6:1693. doi: 10.1016/j.actbio.2009.10.006. [DOI] [PubMed] [Google Scholar]
  • 14.Liu H, Webster TJ. Biomaterials. 2007;28:354. doi: 10.1016/j.biomaterials.2006.08.049. [DOI] [PubMed] [Google Scholar]
  • 15.Mark Kvd, Bauer JPS, Schmuki P. Cell Tissue Res. 2010;339:131. doi: 10.1007/s00441-009-0896-5. [DOI] [PubMed] [Google Scholar]
  • 16.Horley GA. Small. 2006;1:3. [Google Scholar]
  • 17.Whitesides GM. Nat Biotechnol. 2003;21:1161. doi: 10.1038/nbt872. [DOI] [PubMed] [Google Scholar]
  • 18.Rho JY, Spearing LK, Zioupos P. Med Eng Phys. 1998;20:92. doi: 10.1016/s1350-4533(98)00007-1. [DOI] [PubMed] [Google Scholar]
  • 19.Sniadecki NJ, Desai RA, Ruiz SA, Chen CS. Ann Biomed Eng. 2006;34:59. doi: 10.1007/s10439-005-9006-3. [DOI] [PubMed] [Google Scholar]
  • 20.Stevens MM, George JH. Science. 2005;310:1135. doi: 10.1126/science.1106587. [DOI] [PubMed] [Google Scholar]
  • 21.Variola F, Vetrone F, Richert L, Jedrzejowski P, Yi J-H, Zalzal S, Clair S, Sarkissian A, Perepichka DF, Wuest JD, Rosei F, Nanci A. Small. 2009;5:996. doi: 10.1002/smll.200801186. [DOI] [PubMed] [Google Scholar]
  • 22.Barbucci R, Pasqui D, Wirsen A, Affrossman S, Curtis A, Tetta C. J Mater Sci-Mater Med. 2003;14:721. doi: 10.1023/a:1024919917969. [DOI] [PubMed] [Google Scholar]
  • 23.Liu X, Chu PK, Ding C. Mater Sci Eng R. 2004;47:49. [Google Scholar]
  • 24.Guizzardi S, Galli C, Martini D, Belletti S, Tinti A, Raspanti M, Taddei P, Ruggeri A, Scandroglio R. J Periodontol. 2004;75:273. doi: 10.1902/jop.2004.75.2.273. [DOI] [PubMed] [Google Scholar]
  • 25.Anselme K, Bigerelle M. Acta Biomater. 2005;1:211. doi: 10.1016/j.actbio.2004.11.009. [DOI] [PubMed] [Google Scholar]
  • 26.Bigerelle M, Anselme K, Noel B, Ruderman I, Hardouin P, Iost A. Biomaterials. 2002;23:1563. doi: 10.1016/s0142-9612(01)00271-x. [DOI] [PubMed] [Google Scholar]
  • 27.Anselme K, Bigerelle M. J Mater Sci-Mater Med. 2006;17:471. doi: 10.1007/s10856-006-8475-8. [DOI] [PubMed] [Google Scholar]
  • 28.Kim M-J, Choi M-U, Kim C-W. Biomaterials. 2006;27:5502. doi: 10.1016/j.biomaterials.2006.06.023. [DOI] [PubMed] [Google Scholar]
  • 29.Aparicio C, Gil FJ, Planell JA, Engel E. J Mater Sci: Mater Med. 2002;13:1105. doi: 10.1023/a:1021173500990. [DOI] [PubMed] [Google Scholar]
  • 30.Park J-W, Jang I-S, Suh J-Y. J Biomed Mat Res B. 2008;84:400. doi: 10.1002/jbm.b.30884. [DOI] [PubMed] [Google Scholar]
  • 31.Daugaard H, Elmengaard B, Bechtold JE, Soballe K. J Biomed Mat Res A. 2008;87:434. doi: 10.1002/jbm.a.31748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Piattelli A, Celletti R, Marinho VC, Traini T, Orsini G, Bracchetti G, Perrotti V. J Long Term Eff Med Implants. 2006;16:131. doi: 10.1615/jlongtermeffmedimplants.v16.i2.20. [DOI] [PubMed] [Google Scholar]
  • 33.Piattelli M, Scarano A, Paolantonio M, Iezzi G, Petrone G, Piattelli A. J Oral Implantol. 2002;28:2. doi: 10.1563/1548-1336(2002)028<0002:BRTMAR>2.3.CO;2. [DOI] [PubMed] [Google Scholar]
  • 34.Khang D, Lu J, Yao C, Haberstroh KM, Webster TJ. Biomaterials. 2008;29:970. doi: 10.1016/j.biomaterials.2007.11.009. [DOI] [PubMed] [Google Scholar]
  • 35.Mendonça G, Mendonça DBS, Aragao FJL, Cooper LF. Biomaterials. 2008;29:3822. doi: 10.1016/j.biomaterials.2008.05.012. [DOI] [PubMed] [Google Scholar]
  • 36.Kim K-H, Ramaswamy N. Dent Mater J. 2009;28:20. doi: 10.4012/dmj.28.20. [DOI] [PubMed] [Google Scholar]
  • 37.Ercan B, Webster TJ. Biomaterials. 2010;31:3684. doi: 10.1016/j.biomaterials.2010.01.078. [DOI] [PubMed] [Google Scholar]
  • 38.Balasundaram G, Yao C, Webster TJ. J Biomed Mat Res A. 2008;84:447. doi: 10.1002/jbm.a.31388. [DOI] [PubMed] [Google Scholar]
  • 39.Macak JM, Tsuchiya H, Taveira L, Ghicov A, Schmuki P. J Biomed Mat Res A. 2005;75:928. doi: 10.1002/jbm.a.30501. [DOI] [PubMed] [Google Scholar]
  • 40.Yao C, Slamovich EB, Webster TJ. J Biomed Mat Res A. 2008;85:157. doi: 10.1002/jbm.a.31551. [DOI] [PubMed] [Google Scholar]
  • 41.Park J, Bauer S, Schlegel KA, Neukam FW, Mark Kvd, Schmuki P. Small. 2009;5:666. doi: 10.1002/smll.200801476. [DOI] [PubMed] [Google Scholar]
  • 42.Oh S-H, Finones RR, Daraio C, Chen L-H, Jin S. Biomaterials. 2005;26:4938. doi: 10.1016/j.biomaterials.2005.01.048. [DOI] [PubMed] [Google Scholar]
  • 43.Bauer S, Kleber S, Schmuki P. Electrochem Commun. 2006;8:1321. [Google Scholar]
  • 44.Park J, Bauer S, Mark Kvd, Schmuki P. Nano Lett. 2007;7:1686. doi: 10.1021/nl070678d. [DOI] [PubMed] [Google Scholar]
  • 45.He J, Zhou W, Zhou X, Zhong X, Zhang X, Wan P, Zhu B, Chen W. J Mater Sci: Mater Med. 2008;19:3465. doi: 10.1007/s10856-008-3505-3. [DOI] [PubMed] [Google Scholar]
  • 46.Roy SC, Paulose M, Grimes CA. Biomaterials. 2007;28:4667. doi: 10.1016/j.biomaterials.2007.07.045. [DOI] [PubMed] [Google Scholar]
  • 47.Sjostrom T, Dalby MJ, Hart A, Tare R, Oreffo ROC, Su B. Acta Biomater. 2009;5:1433. doi: 10.1016/j.actbio.2009.01.007. [DOI] [PubMed] [Google Scholar]
  • 48.Narayanan R, Kim S-Y, Kwon T-Y, Kim K-H. J Biomed Mater Res Part A. 2008;87:1053. doi: 10.1002/jbm.a.31852. [DOI] [PubMed] [Google Scholar]
  • 49.Lin C, Han H, Zhang F, Li A. J Mater Sci- Mater Med. 2008;19:2569. doi: 10.1007/s10856-007-3196-1. [DOI] [PubMed] [Google Scholar]
  • 50.Vetrone F, Variola F, Oliveira PTd, Zalzal SF, Yi J-H, Sam J, Bombonato-Prado KF, Sarkissian A, Perepichka DF, Wuest JD, Rosei F, Nanci A. Nano Letters. 2009;11:659. doi: 10.1021/nl803051f. [DOI] [PubMed] [Google Scholar]
  • 51.Variola F, Yi J-H, Richert L, Wuest JD, Rosei F, Nanci A. Biomaterials. 2008;29:1285. doi: 10.1016/j.biomaterials.2007.11.040. [DOI] [PubMed] [Google Scholar]
  • 52.Richert L, Vetrone F, Yi J-H, Zalzal SF, Wuest JD, Rosei F, Nanci A. Adv Mat. 2008;20:1488. [Google Scholar]
  • 53.Variola F, Lauria A, Nanci A, Rosei F. Adv Eng Mat. 2009;11:B227. [Google Scholar]
  • 54.Yoshinari M, Oda Y, Kato T, Okuda K. Biomaterials. 2001;22:2043. doi: 10.1016/s0142-9612(00)00392-6. [DOI] [PubMed] [Google Scholar]
  • 55.Cooper LF, Zhou Y, Takebe J, Guo J, Abron A, Holmén A, Ellingsen JE. Biomaterials. 2006;27:926. doi: 10.1016/j.biomaterials.2005.07.009. [DOI] [PubMed] [Google Scholar]
  • 56.Smith LJ, Swaim JS, Yao C, Haberstroh KM, Nauman EA, Webster TJ. Int J Nanomedicine. 2007;2:493. [PMC free article] [PubMed] [Google Scholar]
  • 57.Rani VVD, Manzoor K, Menon D, Selvamurugan N, Nair SV. Nanotechnology. 2010;20:195101. doi: 10.1088/0957-4484/20/19/195101. [DOI] [PubMed] [Google Scholar]
  • 58.Eisenbarth E, Velten D, Breme J. Biomol Eng. 2007;24:27. doi: 10.1016/j.bioeng.2006.05.016. [DOI] [PubMed] [Google Scholar]
  • 59.Popescu S, Demetrescu I, Sarantopoulos C, Gleizes AN, Iordachescu D. J Mater Sci-Mater Med. 2007;18:2075. doi: 10.1007/s10856-007-3133-3. [DOI] [PubMed] [Google Scholar]
  • 60.Eisenbarth E, Velten D, Muller M, Thull R, Breme J. J Biomed Mat Res A. 2006;79:166. doi: 10.1002/jbm.a.30823. [DOI] [PubMed] [Google Scholar]
  • 61.Amaral M, Dias AG, Gomes PS, Lopes MA, Silva RF, Santos JD, Fernandes MH. J Biomed Mat Res A. 2008;87:91. doi: 10.1002/jbm.a.31742. [DOI] [PubMed] [Google Scholar]
  • 62.Das T, Ghosh D, Bhattacharyya TK, Maiti TK. J Mater Sci- Mater Med. 2007;18:493. doi: 10.1007/s10856-007-2009-x. [DOI] [PubMed] [Google Scholar]
  • 63.Roy RK, Lee K-R. J Biomed Mat Res B. 2007;83:72. doi: 10.1002/jbm.b.30768. [DOI] [PubMed] [Google Scholar]
  • 64.Morra M. Eur Cell Mater. 2006;12:1. doi: 10.22203/ecm.v012a01. [DOI] [PubMed] [Google Scholar]
  • 65.Beutner R, Michael J, Schwenzer B, Scharnweber D. J R Soc Interface. 2010;7:S93. doi: 10.1098/rsif.2009.0418.focus. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Schliephake H, Scharnweber D. J Mater Chem. 2008;18:2404. [Google Scholar]
  • 67.Bierbaum S, et al. J Biomed Mat Res A. 2003;67:421. doi: 10.1002/jbm.a.10080. [DOI] [PubMed] [Google Scholar]
  • 68.Ku Y, Chung C-P, Jang J-H. Biomaterials. 2005;26:5153. doi: 10.1016/j.biomaterials.2005.01.060. [DOI] [PubMed] [Google Scholar]
  • 69.Junker R, Dimakis A, Thoneick M, Jansen JA. Clin Oral Implants Res. 2009;20:185. doi: 10.1111/j.1600-0501.2009.01777.x. [DOI] [PubMed] [Google Scholar]
  • 70.O’Toole GC, Salih E, Gallagher C, FitzPatrick D, O’Higgins N, O’Rourke SK. J Orthop Res. 2004;22:641. doi: 10.1016/j.orthres.2003.09.005. [DOI] [PubMed] [Google Scholar]
  • 71.Wikesjö UM, Huang YH, Xiropaidis AV, Sorensen RG, Rohrer MD, Prasad HS, Wozney JM, Hall J. J Clin Periodontol. 2008;35:992. doi: 10.1111/j.1600-051X.2008.01322.x. [DOI] [PubMed] [Google Scholar]
  • 72.Schouten C, Meijer GJ, Beucken JJvd, Spauwen PH, Jansen JA. Clin Oral Implants Res. 2009;20:421. doi: 10.1111/j.1600-0501.2008.01657.x. [DOI] [PubMed] [Google Scholar]
  • 73.Susin C, Qahash M, Polimeni G, Lu PH, Prasad HS, Rohrer MD, Hall J, Wikesjö UM. J Clin Periodontol. 2010;37:574. doi: 10.1111/j.1600-051X.2010.01554.x. [DOI] [PubMed] [Google Scholar]
  • 74.Bussy C, Verhoef R, Haeger A, Morra M, Duval JL, Vigneron P, Bensoussan A, Velzenberger E, Cascardo G, Cassinelli C, Schols H, Knox JP, Nagel MD. J Biomed Mater Res A. 2008;86:597. doi: 10.1002/jbm.a.31729. [DOI] [PubMed] [Google Scholar]
  • 75.Bumgardner JD, Chesnutt BM, Yuan Y, Yang Y, Appleford M, Oh S, McLaughlin R, Elder SH, Ong JL. Implant Dent. 2007;16:66. doi: 10.1097/ID.0b013e3180312011. [DOI] [PubMed] [Google Scholar]
  • 76.Greene AH, Bumgardner JD, Yang Y, Moseley J, Haggard WO. Clin Orthop Relat Res. 2008;466:1699. doi: 10.1007/s11999-008-0269-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Caro A, Humblot V, Méthivier C, Minier M, Salmain M, Pradier CM. J Phys Chem B. 2009;113:2101. doi: 10.1021/jp805284s. [DOI] [PubMed] [Google Scholar]
  • 78.Cardenas G, Anaya P, Plessing Cv, Rojas C, Sepulveda J. J Mater Sci-Mater Med. 2008;19:2397. doi: 10.1007/s10856-007-3275-3. [DOI] [PubMed] [Google Scholar]
  • 79.Martin HJ, Schulz KH, Bumgardner JD, Walters KB. Langmuir. 2007;23:6645–6651. doi: 10.1021/la063284v. [DOI] [PubMed] [Google Scholar]
  • 80.Antoci V, Adams CS, Parvizi J, Ducheyne P, Shapiro IM, Hickok NJ. Clin Orthop Relat Res. 2007;461:81. doi: 10.1097/BLO.0b013e3181123a50. [DOI] [PubMed] [Google Scholar]
  • 81.Antoci V, King SB, Jose B, Parvizi J, Zeiger AR, Wickstrom E, Freeman TA, Composto RJ, Ducheyne P, Shapiro IM, Hickok NJ, Adams CS. J Orthop Res. 2007;25:858. doi: 10.1002/jor.20348. [DOI] [PubMed] [Google Scholar]
  • 82.Darouiche RO, Mansouri MD, Zakarevicz D, AlSharif A, Landon GC. J Bone Joint Surg Am. 2007;89:792. doi: 10.2106/JBJS.F.00414. [DOI] [PubMed] [Google Scholar]
  • 83.Chun AL, Moralez JG, Webster TJ, Fenniri H. Biomaterials. 2005;26:7304. doi: 10.1016/j.biomaterials.2005.05.080. [DOI] [PubMed] [Google Scholar]
  • 84.Chun AL, Moralez JG, Fenniri H, Webster TJ. Nanotechnology. 2004;15:S234. [Google Scholar]
  • 85.Jansson E, Tengvall P. Colloids Surf B. 2004;35:45. doi: 10.1016/j.colsurfb.2004.02.007. [DOI] [PubMed] [Google Scholar]
  • 86.Muller R, Abke J, Schnell E, Scharnweber D, Kujat R, Englert C, Taheri D, Nerlich M, Angele P. Biomaterials. 2006;27:4059. doi: 10.1016/j.biomaterials.2006.03.019. [DOI] [PubMed] [Google Scholar]
  • 87.Nanci A, et al. J Biomed Mat Res. 1998;40:324. doi: 10.1002/(sici)1097-4636(199805)40:2<324::aid-jbm18>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  • 88.Toworfe GK, Bhattacharyya S, Composto RJ, Adams CS, Shapiro IM, Ducheyne P. J Tissue Eng Reg Med. 2009;3:26. doi: 10.1002/term.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Viornery C, et al. J Biomed Mat Res. 2002;62:149. doi: 10.1002/jbm.10205. [DOI] [PubMed] [Google Scholar]
  • 90.Falconnet D, Csucs G, Grandin HM, Textor M. Biomaterials. 2006;27:3044. doi: 10.1016/j.biomaterials.2005.12.024. [DOI] [PubMed] [Google Scholar]
  • 91.Monchaux E, Vermette P. J Biomed Mater Res A. 2008;85:1052. doi: 10.1002/jbm.a.31580. [DOI] [PubMed] [Google Scholar]
  • 92.Sask KN, Zhitomirsky I, Berry LR, Chan AK, Brash JL. Acta Biomater. 2010 doi: 10.1016/j.actbio.2010.02.043. in Press. [DOI] [PubMed] [Google Scholar]
  • 93.Jeyachandran YL, Mielczarski JA, Mielczarski E, Rai B. J Colloid Interface Sci. 2010;341:136. doi: 10.1016/j.jcis.2009.09.007. [DOI] [PubMed] [Google Scholar]
  • 94.Kim TG, Lee Y, Park TG. Int J Pharm. 2010;384:181. doi: 10.1016/j.ijpharm.2009.09.042. [DOI] [PubMed] [Google Scholar]
  • 95.Mahapatro A, Johnson DM, Patel DN, Feldman MD, Ayon AA, Agrawal CM. Curr Top Med Chem. 2008;8:281. doi: 10.2174/156802608783790929. [DOI] [PubMed] [Google Scholar]
  • 96.Nakano K, Egashira K, Masuda S, Funakoshi K, Zhao G, Kimura S, Matoba T, Sueishi K, Endo Y, Kawashima Y, Hara K, Tsujimoto H, Tominaga R, Sunagawa K. JACC Cardiovasc Interv. 2009;2:277. doi: 10.1016/j.jcin.2008.08.023. [DOI] [PubMed] [Google Scholar]
  • 97.Reising A, Yao C, Storey D, Webster TJ. J Biomed Mater Res. 2008;87A:78–83. doi: 10.1002/jbm.a.31772. [DOI] [PubMed] [Google Scholar]
  • 98.Großner-Schreiber B, Herzog M, Hedderich J, Duck A, Hannig M, Griepentrog M. Clin Oral Impl Res. 2006;17:736. doi: 10.1111/j.1600-0501.2006.01277.x. [DOI] [PubMed] [Google Scholar]
  • 99.Ogawa T, Saruwatari L, Takeuchi K, Aita H, Ohno N. J Dent Res. 2008;87:751. doi: 10.1177/154405910808700809. [DOI] [PubMed] [Google Scholar]
  • 100.Hovgaard M, Chevallier J, Foss M, Besenbacher F. Appl Phys Lett. 2005;87:073105. [Google Scholar]
  • 101.Rautray TR, Narayanan R, Kwon T-Y, Kim K-H. J Biomed Mater Res Part B: Applied Biomater. 2010 doi: 10.1002/jbm.b.31596. in Press. [DOI] [PubMed] [Google Scholar]
  • 102.Hanawa T. Mater Sci Eng A. 1999;267:260. [Google Scholar]
  • 103.Hanawa T, Kamiura Y, Yamamoto S, Kohgo T, Amemiya A, Ukai H, Murakami K, Asaoka K. J Biomed Mater Res. 1997;36:131. doi: 10.1002/(sici)1097-4636(199707)36:1<131::aid-jbm16>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  • 104.Saldana L, Barranco V, Gonzalez-Carrasco JL, Rodriguez M, Munuera L, Vilaboa N. J Biomed Mater Res A. 2007;81:334. doi: 10.1002/jbm.a.30994. [DOI] [PubMed] [Google Scholar]
  • 105.Saldana L, Vilaboa N, Valles G, Gonzalez-Cabrero J, Munuera L. J Biomed Mater Res A. 2005;73:97. doi: 10.1002/jbm.a.30264. [DOI] [PubMed] [Google Scholar]
  • 106.Engler AJ, Humbert PO, Wehrle-Haller B, Weaver VM. Science. 2009;324:208–212. doi: 10.1126/science.1170107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Kasemo B. Surf Sci. 2002;500:656. [Google Scholar]
  • 108.Anselme K. Biomaterials. 2000;21:667. doi: 10.1016/s0142-9612(99)00242-2. [DOI] [PubMed] [Google Scholar]
  • 109.Puleo DA, Nanci A. Biomaterials. 1999;20:2311. doi: 10.1016/s0142-9612(99)00160-x. [DOI] [PubMed] [Google Scholar]
  • 110.Kasemo B, Gold J. Adv Dent Res. 1999;13:8. doi: 10.1177/08959374990130011901. [DOI] [PubMed] [Google Scholar]
  • 111.Hori N, Att W, Ueno T, Sato N, Yamada M, Saruwatari L, Suzuki T, Ogawa T. J Dent Res. 2009;88:663. doi: 10.1177/0022034509339567. [DOI] [PubMed] [Google Scholar]
  • 112.Nagassa ME, Daw AE, Rowe WG, Carley A, Thomas DW, Moseley R. Clin Oral Implants Res. 2008;19:1317. doi: 10.1111/j.1600-0501.2008.01611.x. [DOI] [PubMed] [Google Scholar]
  • 113.Wilson CJ, Clegg RE, Leavesley DI, Pearcy MJ. TIssue Eng. 2005;11:1. doi: 10.1089/ten.2005.11.1. [DOI] [PubMed] [Google Scholar]
  • 114.Gugutkov D, Altankov G, Hernández JCR, Pradas MM, Sánchez MS. J Biomed Mater Res A. 2010;92:322. doi: 10.1002/jbm.a.32374. [DOI] [PubMed] [Google Scholar]
  • 115.Sela MN, Badihi L, Rosen G, Steinberg D, Kohavi D. Clin Oral Implants Res. 2007;18:630. doi: 10.1111/j.1600-0501.2007.01373.x. [DOI] [PubMed] [Google Scholar]
  • 116.Roach P, Farrar D, Perry CC. J Am Chem Soc. 2006;128:3939. doi: 10.1021/ja056278e. [DOI] [PubMed] [Google Scholar]
  • 117.Hemmersam AG, Foss M, Chevallier J, Besenbacher F. Colloids Surf. 2005;43:208. doi: 10.1016/j.colsurfb.2005.04.007. [DOI] [PubMed] [Google Scholar]
  • 118.Denis FA, Hanarp P, Sutherland DS, Gold J, Mustin C, Rouxhet PG, Dufrene YF. Langmuir. 2002;18:819. [Google Scholar]
  • 119.Dolatshahi-Pirouz A, Rechendorff K, Hovgaard MB, Foss M, Chevallier J, Besenbacher F. Colloids Surf, B. 2008;66:53. doi: 10.1016/j.colsurfb.2008.05.010. [DOI] [PubMed] [Google Scholar]
  • 120.Hovgaard MB, Rechendorff K, Chevallier J, Foss M, Besenbacher F. J Phys Chem B. 2008;112:8241. doi: 10.1021/jp801103n. [DOI] [PubMed] [Google Scholar]
  • 121.Rechendorff K, Hovgaard MB, Foss M, Zhdanov VP, Besenbacher F. Langmuir. 2006;22:10885. doi: 10.1021/la0621923. [DOI] [PubMed] [Google Scholar]
  • 122.Richert L, Variola F, Rosei F, Wuest JD, Nanci A. Surf Sci. 2010;604:1445. [Google Scholar]
  • 123.Cai K, Bossert J, Biointerfaces KDJCSB. Colloids Surf B Biointerfaces. 2006;49:136. doi: 10.1016/j.colsurfb.2006.02.016. [DOI] [PubMed] [Google Scholar]
  • 124.Carpenter J, Khang D, Webster TJ. Nanotechnology. 2008;19:505103. doi: 10.1088/0957-4484/19/50/505103. [DOI] [PubMed] [Google Scholar]
  • 125.González-García C, Sousa SR, Moratal D, Rico P, Salmerón-Sánchez M. Colloids Surf B Biointerfaces. 2010 doi: 10.1016/j.colsurfb.2010.01.021. in Press. [DOI] [PubMed] [Google Scholar]
  • 126.Pollard TD, Earnshaw WC. Cell Biology. 2002 [Google Scholar]
  • 127.Ercan B, Webster TJ. Int J Nanomed. 2008;3:477. doi: 10.2147/ijn.s3780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128.Chiang C-Y, Chiou S-H, Yang W-E, Hsu M-L, Yung M-C, Tsai M-L, Chen L-K, Huang H-H. Dental Mater. 2009;25:1022. doi: 10.1016/j.dental.2009.03.001. [DOI] [PubMed] [Google Scholar]
  • 129.Bauer S, Park J, Faltenbacher J, Berger S, Mark Kvd, Schmuki P. Integr Biol. 2009;1:525. doi: 10.1039/b908196h. [DOI] [PubMed] [Google Scholar]
  • 130.Park J, Bauer S, Schmuki P, Mark Kvd. Nano Lett. 2009;9:3157. doi: 10.1021/nl9013502. [DOI] [PubMed] [Google Scholar]
  • 131.Burns K, Yao C, Webster TJ. J Biomed Mater Res. 2009;88A:561. doi: 10.1002/jbm.a.31899. [DOI] [PubMed] [Google Scholar]
  • 132.Puckett SD, Lee PP, Ciombor DM, Aaron RK, Webster TJ. Acta Biomater. 2010;6:2352. doi: 10.1016/j.actbio.2009.12.016. [DOI] [PubMed] [Google Scholar]
  • 133.Puckett SD, Taylor E, Raimondo T, Webster TJ. Biomaterials. 2010;31:706. doi: 10.1016/j.biomaterials.2009.09.081. [DOI] [PubMed] [Google Scholar]
  • 134.Price RL, Ellison K, Haberstroh KM, Webster TJ. J Biomed Mater Res A. 2004;70:129. doi: 10.1002/jbm.a.30073. [DOI] [PubMed] [Google Scholar]
  • 135.Oliveira PTd, Nanci A. Biomaterials. 2004;25:403. doi: 10.1016/s0142-9612(03)00539-8. [DOI] [PubMed] [Google Scholar]
  • 136.Oliveira PTD, Zalzal SF, Beloti MM, Rosa AL, Nanci A. J Biomed Mater Res. 2007;80A:554. doi: 10.1002/jbm.a.30955. [DOI] [PubMed] [Google Scholar]
  • 137.Gingell D. Symp Soc Exp Biol. 1993;47:1. [PubMed] [Google Scholar]
  • 138.Sechler JL, Corbett SA, Wenk MB, Schwarzbauer JE. Ann NY Acad Sci. 1998;857:143. doi: 10.1111/j.1749-6632.1998.tb10114.x. [DOI] [PubMed] [Google Scholar]
  • 139.Sepulveda JL, Gkretsi V, Wu C. Curr Top Dev Biol. 2005;68:183. doi: 10.1016/S0070-2153(05)68007-6. [DOI] [PubMed] [Google Scholar]
  • 140.Mao Y, Schwarzbauer JE. Matrix Biol. 2005;24:389. doi: 10.1016/j.matbio.2005.06.008. [DOI] [PubMed] [Google Scholar]
  • 141.Mendonça G, Mendonça DB, Aragão FJ, Cooper LF. J Biomed Mater Res A. 2010;94:169. doi: 10.1002/jbm.a.32701. [DOI] [PubMed] [Google Scholar]
  • 142.Bajgai MP, Parajuli DC, Park S-J, Chu KH, Kang H-S, Kim HY. J Mater Sci: Mater Med. 2010;21:685. doi: 10.1007/s10856-009-3902-2. [DOI] [PubMed] [Google Scholar]
  • 143.Tosatti S, et al. J Biomed Mat Res A. 2004;68:458. doi: 10.1002/jbm.a.20082. [DOI] [PubMed] [Google Scholar]
  • 144.Balasundaram G, Webster TJ. J Biomed Mat Res A. 2007;80:602. doi: 10.1002/jbm.a.30954. [DOI] [PubMed] [Google Scholar]
  • 145.Secchi AG, et al. J Biomed Mat Res A. 2007;83:577. doi: 10.1002/jbm.a.31007. [DOI] [PubMed] [Google Scholar]
  • 146.Auernheimer J, et al. BioChem. 2005;6:2034. [Google Scholar]
  • 147.Douglas T, Heinemann S, Hempel U, Mietrach C, Knieb C, Bierbaum S, Scharnweber D, Worch H. J Mater Sci: Mater Med. 2008;19:1653. doi: 10.1007/s10856-007-3250-z. [DOI] [PubMed] [Google Scholar]
  • 148.Hacking SA, Zuraw M, Harvey EJ, Tanzer M, Krygier JJ, Bobyn JD. J Biomed Mater Res A. 2007;82:179. doi: 10.1002/jbm.a.31131. [DOI] [PubMed] [Google Scholar]
  • 149.Takagi J, Petre BM, Walz T, Springer TA. Cell. 2002;110:599. doi: 10.1016/s0092-8674(02)00935-2. [DOI] [PubMed] [Google Scholar]
  • 150.Alberts B. Molecular biology of the cell. 5. 2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 151.Wang YL, Discher DE. Methods in Cell Biology - Cell Mechanics. Academic Press-Elsevier; Oxford, UK: 2007. [Google Scholar]
  • 152.Biggs MJP, Richards RG, Dalby MJ. Nanomedicine: Nanotechnology, Biology, and Medicine. 2010 doi: 10.1016/j.nano.2010.01.009. in Press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 153.Girard PP, Cavalcanti-Adam EA, Kemkemer R, Spatz JP. Soft Matter. 2007;3:307. doi: 10.1039/b614008d. [DOI] [PubMed] [Google Scholar]
  • 154.Bustelo XR, Sauzeau V, Berenjeno IM. BioEssays. 2007;29:356. doi: 10.1002/bies.20558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 155.Watt FM, Jordan PW, O’Neill CH. Proc Natl Acad Sci USA. 1988;85:5576. doi: 10.1073/pnas.85.15.5576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 156.Adams JC, Watt FM. Development. 1993;117:1183. doi: 10.1242/dev.117.4.1183. [DOI] [PubMed] [Google Scholar]
  • 157.Roskelley CD, Desprez PY, Bissell MJ. Proc Natl Acad Sci USA. 1994;91:12378. doi: 10.1073/pnas.91.26.12378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 158.Chen CS, Mrksich M, Huang S, Whitesides GM, Ingber DE. Science. 1997;276:1425. doi: 10.1126/science.276.5317.1425. [DOI] [PubMed] [Google Scholar]
  • 159.Chen CS, Alonso JL, Ostuni E, Whitesides GM, Ingber DE. Biochem Biophys Res Commun. 2003;307:355. doi: 10.1016/s0006-291x(03)01165-3. [DOI] [PubMed] [Google Scholar]
  • 160.McBeath R, Pirone DM, Nelson CM, Bhadriraju K, Chen CS. Dev Cell. 2004;6:483. doi: 10.1016/s1534-5807(04)00075-9. [DOI] [PubMed] [Google Scholar]
  • 161.Albrektsson T, Wennerberg A. Int J Prosthodont. 2004;17:544. [PubMed] [Google Scholar]
  • 162.Shalabi MM, Gortemaker A, Hof MAVt, Jansen JA, Creugers NH. J Dent Res. 2006;85:496. doi: 10.1177/154405910608500603. [DOI] [PubMed] [Google Scholar]
  • 163.Sul YT, Johansson C, Wennerberg A, Cho LR, Chang BS, Albrektsson T. Int J Oral Maxillofac Implants. 2005;20:349. [PubMed] [Google Scholar]
  • 164.Davies JE. J Dent Educ. 2003;67:932. [PubMed] [Google Scholar]
  • 165.Park JY, Davies JE. Clin Oral Implants Res. 2000;11:530. doi: 10.1034/j.1600-0501.2000.011006530.x. [DOI] [PubMed] [Google Scholar]
  • 166.Boyan BD, Lossdorfer S, Wang L, Zhao G, Lohmann CH, Cochran DL, Schwartz Z. Eur Cell Mater. 2003;6:22. doi: 10.22203/ecm.v006a03. [DOI] [PubMed] [Google Scholar]
  • 167.Kieswetter K, Schwartz Z, Hummert TW, Cochran DL, Simpson J, Dean DD, Boyan BD. J Biomed Mater Res. 1996;32:55. doi: 10.1002/(SICI)1097-4636(199609)32:1<55::AID-JBM7>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  • 168.Wilmowsky Cv, Bauer S, Lutz R, Meisel M, Neukam FW, Toyoshima T, et al. J Biomed Mater Res B Appl Biomater. 2009;89:165. doi: 10.1002/jbm.b.31201. [DOI] [PubMed] [Google Scholar]
  • 169.Jäger M, Zilkens C, Zanger K, Krauspe R. J Biomed Biotechnol. 2007;2007:69036. doi: 10.1155/2007/69036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 170.Guehennec LL, Soueidan A, Layrolle P, Amouriq Y. Dental Mat. 2007;23:844. doi: 10.1016/j.dental.2006.06.025. [DOI] [PubMed] [Google Scholar]
  • 171.Park KH, Heo SJ, Koak JY, Kim SK, Lee JB, Kim SH, Lim YJ. J Oral Rehab. 2007;34:517. doi: 10.1111/j.1365-2842.2006.01688.x. [DOI] [PubMed] [Google Scholar]
  • 172.Yang GL, FM FMH, Hu JA, Wang XX, Zhao SF. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107:782. doi: 10.1016/j.tripleo.2008.12.023. [DOI] [PubMed] [Google Scholar]
  • 173.Meirelles L, Arvidsson A, Andersson M, Kjellin P, Albrektsson T, Wennerberg A. J Biomed Mater Res A. 2008;87:299. doi: 10.1002/jbm.a.31744. [DOI] [PubMed] [Google Scholar]
  • 174.Meirelles L, Melin L, Peltola T, Kjellin P, Kangasniemi I, Currie F, Andersson M, Albrektsson T, Wennerberg A. Clin Implant Dent Relat Res. 2008;10:254. doi: 10.1111/j.1708-8208.2008.00089.x. [DOI] [PubMed] [Google Scholar]
  • 175.Sul YT, Jönsson J, Yoon GS, Johansson C. Clin Oral Implants Res. 2009;20:1146. doi: 10.1111/j.1600-0501.2009.01767.x. [DOI] [PubMed] [Google Scholar]
  • 176.Sul YT, Kang BS, Johansson B, Um HS, Park CJ, Albrektsson T. J Biomed Mater Res A. 2009;89:942. doi: 10.1002/jbm.a.32041. [DOI] [PubMed] [Google Scholar]
  • 177.Sul YT, Johansson CB, Byon E, Albrektsson T. Biomaterials. 2005;26:6720. doi: 10.1016/j.biomaterials.2005.04.058. [DOI] [PubMed] [Google Scholar]
  • 178.Sul YT, Johansson CB, Albrektsson T. Int J Prosthodont. 2006;19:319. [PubMed] [Google Scholar]
  • 179.Tavares MG, Oliveira PTd, Nanci A, Hawthorne AC, Rosa AL, Xavier SPr. Clin Oral Impl Res. 2007;18:452. doi: 10.1111/j.1600-0501.2007.01344.x. [DOI] [PubMed] [Google Scholar]
  • 180.Guo J, Padilla RJ, Ambrose W, Kok IJD, Cooper LF. Biomaterials. 2007;28:5418. doi: 10.1016/j.biomaterials.2007.08.032. [DOI] [PubMed] [Google Scholar]
  • 181.Ellingsen JE, Johansson CB, Wennerberg A, Holmen A. Int J Oral Maxillofac Implants. 2004;19:656. [PubMed] [Google Scholar]
  • 182.Berglundh T, Abrahamsson I, Albouy JP, Lindhe J. Clin Oral Implants Res. 2007;18:147. doi: 10.1111/j.1600-0501.2006.01309.x. [DOI] [PubMed] [Google Scholar]
  • 183.Abrahamsson I, Albouy JP, Berglundh T. Clin Oral Implants Res. 2008;19:153. doi: 10.1111/j.1600-0501.2007.01454.x. [DOI] [PubMed] [Google Scholar]
  • 184.Stanford CM, Johnson GK, Fakhry A, Gratton D, Mellonig JT, Wanger W. Appl Osseointegration Res. 2006;5:50. [Google Scholar]
  • 185.Oxby G, Lindqvist J, Nilsson P. Appl Osseointegration Res. 2006;5:68. [Google Scholar]
  • 186.Mendes VC, Moineddin R, Davies JE. Biomaterials. 2007;28:4748. doi: 10.1016/j.biomaterials.2007.07.020. [DOI] [PubMed] [Google Scholar]
  • 187.Orsini G, Piattelli M, Scarano A, Petrone G, Kenealy J, Piattelli A, et al. J Periodontol. 2007;78:209. doi: 10.1902/jop.2007.060297. [DOI] [PubMed] [Google Scholar]
  • 188.Goené RJ, Testori T, Trisi P. Int J Periodontics Restorative Dent. 2007;27:211. [PubMed] [Google Scholar]
  • 189.Vignoletti F, Sanctis Md, Berglundh T, Abrahamsson I, Sanz M. J Clin Periodontol. 2009;36:688. doi: 10.1111/j.1600-051X.2009.01439.x. [DOI] [PubMed] [Google Scholar]
  • 190.Coelho PG, Cardaropoli G, Suzuki M, Lemons JE. J Biomed Mater Res B Appl Biomater. 2009;88:387. doi: 10.1002/jbm.b.31090. [DOI] [PubMed] [Google Scholar]
  • 191.Granato R, Marin C, Gil JN, Chuang SK, Dodson TB, Suzuki M, Coelho PG. Clin Implant Dent Relat Res. 2009 doi: 10.1111/j.1708-8208.2009.00186.x. In press. [DOI] [PubMed] [Google Scholar]
  • 192.Park JW, Kim HK, Kim YJ, An CH, Hanawa T. Clin Oral Implants Res. 2009;20:684. doi: 10.1111/j.1600-0501.2009.01714.x. [DOI] [PubMed] [Google Scholar]
  • 193.Park J-W, Suh J-Y, Chung H-J. J Biomed Mater Res A. 2008;86:117. doi: 10.1002/jbm.a.31618. [DOI] [PubMed] [Google Scholar]
  • 194.Suh J-Y, Jeung O-C, Choi B-J, Park J-W. Clin Oral Impants Res. 2007;18:362. doi: 10.1111/j.1600-0501.2006.01323.x. [DOI] [PubMed] [Google Scholar]
  • 195.Marin C, Granato R, Suzuki M, Gil JN, Piattelli A, Coelho PG. J Periodontol. 2008;79:1942. doi: 10.1902/jop.2008.080106. [DOI] [PubMed] [Google Scholar]
  • 196.Shibli JA, Grassi S, Piattelli A, Pecora GE, Ferrari DS, Onuma T, d’Avila S, Coelho PG, Barros R, Iezzi G. Clin Implant Dent Relat Res. 2009 doi: 10.1111/j.1708-8208.2009.00174.x. [DOI] [PubMed] [Google Scholar]
  • 197.Hetrick EM, Schoenfisch MH. Chem Soc Rev. 2006;35:780. doi: 10.1039/b515219b. [DOI] [PubMed] [Google Scholar]
  • 198.Zhao L, Chu PK, Zhang Y, Wu Z. J Biomed Mater Res Part B: Appl Biomater. 2009;91B:470. doi: 10.1002/jbm.b.31463. [DOI] [PubMed] [Google Scholar]
  • 199.Lucke M, Schmidmaier G, Sadoni S, Wildemann B, Schiller R, Haas NP, Raschke M. Bone. 2003;32:521. doi: 10.1016/s8756-3282(03)00050-4. [DOI] [PubMed] [Google Scholar]
  • 200.Hanawa T. J Artificial Organs. 2009;12:73. doi: 10.1007/s10047-008-0456-x. [DOI] [PubMed] [Google Scholar]
  • 201.Puskas JE, Muñoz-Robledo LG, Hoerr RA, Foley J, Schmidt SP, Evancho-Chapman M, Dong J, Frethem C, Haugstad G. Nanomedicine and Nanobiotechnology. 2009;1:451. doi: 10.1002/wnan.38. [DOI] [PubMed] [Google Scholar]
  • 202.Tsujino I, Ako J, Honda Y, Fitzgerald PJ. Expert Opinion on Drug Delivery. 2007;4:287. doi: 10.1517/17425247.4.3.287. [DOI] [PubMed] [Google Scholar]
  • 203.Wieneke H, Dirsch O, Sawitowski T, et al. Catheter Cardiovasc Interv. 2003;60:399. doi: 10.1002/ccd.10664. [DOI] [PubMed] [Google Scholar]
  • 204.Grube E. American College of Cardiology meeting; Chicago, USA. 2003. [Google Scholar]
  • 205.Gottlow J. The implant design and biological response. Wiley-Blackwell; Iowa: 2009. [Google Scholar]
  • 206.Simmons CA, Meguid SA, Pilliar RM. J Biomed Mater Res. 2001;55:63. doi: 10.1002/1097-4636(200104)55:1<63::aid-jbm90>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  • 207.Mouzin O, Soballe K, Bechtold JE. J Biomed Mater Res. 2001;58:61. doi: 10.1002/1097-4636(2001)58:1<61::aid-jbm90>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  • 208.Simmons CA, Meguid SA, Pilliar RM. J Orthop Res. 2001;19:187. doi: 10.1016/S0736-0266(00)90006-8. [DOI] [PubMed] [Google Scholar]
  • 209.Van OH, Duyck J, Vander SJ, Perre GVD, De SLCM, Puers R, Naert I. Clin Oral Implants Res. 1998;9:407. doi: 10.1034/j.1600-0501.1996.090606.x. [DOI] [PubMed] [Google Scholar]
  • 210.De SE, Jaecques S, Vandamme K, Vander SJ, Naert I. Clin Oral Implants Res. 2005;16:402. doi: 10.1111/j.1600-0501.2005.01156.x. [DOI] [PubMed] [Google Scholar]
  • 211.Duyck J, Slaets E, Sasaguri K, Vandamme K, Naert I. J Clin Periodontol. 2007;34:998. doi: 10.1111/j.1600-051X.2007.01135.x. [DOI] [PubMed] [Google Scholar]
  • 212.Duyck J, Vandamme K, Geris L, Van OH, De CM, Vandersloten J, Puers R, Naert I. Arch Oral Biol. 2006;51:1. doi: 10.1016/j.archoralbio.2005.04.003. [DOI] [PubMed] [Google Scholar]
  • 213.Rubin CT, McLeod KJ. Clin Orthop Relat Res. 1994:165. [PubMed] [Google Scholar]
  • 214.Szmukler-Moncler S, Salama H, Reingewirtz Y, Dubruille JH. J Biomed Mater Res. 1998;43:192. doi: 10.1002/(sici)1097-4636(199822)43:2<192::aid-jbm14>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  • 215.Vandamme K, Naert I, Geris L, Vander SJ, Puers R, Duyck J. J Clin Periodontol. 2007;34:172. doi: 10.1111/j.1600-051X.2006.01014.x. [DOI] [PubMed] [Google Scholar]
  • 216.Brunski JB. Adv Dent Res. 1999;13:99. doi: 10.1177/08959374990130012301. [DOI] [PubMed] [Google Scholar]
  • 217.Leucht P, Kim JB, Wazen R, Currey JA, Nanci A, Brunski JB, Helms JA. Bone. 2006;40:919. doi: 10.1016/j.bone.2006.10.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 218.Jokstad A, Braegger U, Brunski JB, Carr AB, Naert I, Wennerberg A. Int Dent J. 2003;53:409. doi: 10.1111/j.1875-595x.2003.tb00918.x. [DOI] [PubMed] [Google Scholar]
  • 219.Loboa EG, Fang TD, Warren SM, Lindsey DP, Fong KD, Longaker MT, Carter DR. Bone. 2004;34:336. doi: 10.1016/j.bone.2003.10.012. [DOI] [PubMed] [Google Scholar]
  • 220.Humphrey JD. J Biomech Eng. 2001;123:638. doi: 10.1115/1.1406131. [DOI] [PubMed] [Google Scholar]
  • 221.Brunski JB, Currey JA, Helms JA, Leucht P, Nanci A, Wazen RM. The healing bone-implant interface: role of micromotion and related strain levels in tissue. A. Jokstad; Iowa: 2008. [Google Scholar]
  • 222.Claes L, Blakytny R, Göckelmann M, Schoen M, Ignatius A, Willie B. J Orthop Res. 2009;27:22. doi: 10.1002/jor.20712. [DOI] [PubMed] [Google Scholar]
  • 223.Claes LE, Wilke HJ, Augat P, Rübenacker S, Margevicius KJ. Clin Biomech (Bristol, Avon) 1995;10:227. doi: 10.1016/0268-0033(95)99799-8. [DOI] [PubMed] [Google Scholar]
  • 224.Claes L, Schorlemmer PAPS, Konrads C, Ignatius A, Ehrnthaller C. J Orthop Res. 2008;26:772. doi: 10.1002/jor.20588. [DOI] [PubMed] [Google Scholar]
  • 225.Albrektsson T, Wennerberg A. Int J Prosthodont. 2004;17:536. [PubMed] [Google Scholar]
  • 226.Leven RM, Virdi AS, Sumner DR. J Biomed Mater Res A. 2004;70:391. doi: 10.1002/jbm.a.30082. [DOI] [PubMed] [Google Scholar]
  • 227.Masaki C, Schneider GB, Zaharias R, Seabold D, Stanford C. Clin Oral Implants Res. 2005;16:650. doi: 10.1111/j.1600-0501.2005.01170.x. [DOI] [PubMed] [Google Scholar]
  • 228.Ogawa T, Nishimura I. J Dent Res. 2006;85:566. doi: 10.1177/154405910608500617. [DOI] [PubMed] [Google Scholar]
  • 229.Isa ZM, Schneider GB, Zaharias R, Seabold D, Stanford CM. Int J Maxillofac Implants. 2006;21:203. [PubMed] [Google Scholar]
  • 230.Discher DE, Mooney DJ, Zandstra PW. Science. 2009;324:1673. doi: 10.1126/science.1171643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 231.Leucht P, Kim JB, Currey JA, Brunski JB, Helms JA. PLoS One. 2007;2:e390-391-e390. doi: 10.1371/journal.pone.0000390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 232.Yim EK, Leong KW. Nanomedicine. 2005;1:10. doi: 10.1016/j.nano.2004.11.008. [DOI] [PubMed] [Google Scholar]
  • 233.Dalby MJ, McCloy D, Robertson M, Agheli H, Sutherland D, Affrossman S, Oreffo RO. Biomaterials. 2006;27:2980. doi: 10.1016/j.biomaterials.2006.01.010. [DOI] [PubMed] [Google Scholar]
  • 234.Hansen JC, Lim JY, Xu LC, Siedlecki CA, Mauger DT, Donahue HJ. J Biomech. 2007;40:2865. doi: 10.1016/j.jbiomech.2007.03.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 235.Sargeant A, Goswami T. Materials and Design. 2007;28:155. [Google Scholar]
  • 236.Li Y, Wong C, Xiong J, Hodgson P, Wen C. J Dent Res. 2010;89:493. doi: 10.1177/0022034510363675. [DOI] [PubMed] [Google Scholar]
  • 237.Donato TAG, Almeida LHd, Nogueira RA, Niemeyer TC, Grandini CR, Caram R, Schneider SG, Santos AR. Mat Sci Eng C-Bio S. 2009;29:1365. [Google Scholar]
  • 238.Lim JY, Dreiss AD, Zhou Z, Hansen JC, Siedlecki CA, Hengstebeck RW, Cheng J, Winograd N, Donahue HJ. Biomaterials. 2007;28:1787. doi: 10.1016/j.biomaterials.2006.12.020. [DOI] [PubMed] [Google Scholar]
  • 239.Das K, Bose S, Bandyopadhyay A. J Biomed Mater Res. 2009;90A:225. doi: 10.1002/jbm.a.32088. [DOI] [PubMed] [Google Scholar]
  • 240.Noh H, Vogler EA. Biomaterials. 2007;28:405. doi: 10.1016/j.biomaterials.2006.09.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 241.Alves CM, Reis RL, Hunt JA. J R Soc Interface. 2010;7:1367. doi: 10.1098/rsif.2010.0022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 242.Anderson, et al. Semin Immunol. 2008;20:86. doi: 10.1016/j.smim.2007.11.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 243.Wazen RM, Tye CE, Goldberg HA, Hunter GK, Smith CE, Nanci A. J Histochem Cytochem. 2007;55:35. doi: 10.1369/jhc.6A7046.2006. [DOI] [PubMed] [Google Scholar]
  • 244.Cochran DL. J Periodontol. 1999;70:1523. doi: 10.1902/jop.1999.70.12.1523. [DOI] [PubMed] [Google Scholar]
  • 245.Morton D, Jaffin R, Weber HP. Int J Oral Maxillofac Implants. 2004;19(Suppl):103. [PubMed] [Google Scholar]
  • 246.Tolstunov L. Implant Dent. 2006;15:341. doi: 10.1097/01.id.0000239333.24384.5d. [DOI] [PubMed] [Google Scholar]
  • 247.Jaffin RA, Berman CL. J Periodontol. 1991;62:2. doi: 10.1902/jop.1991.62.1.2. [DOI] [PubMed] [Google Scholar]
  • 248.Bain CA. Int J Oral Maxillofac Implants. 1996;11:756. [PubMed] [Google Scholar]
  • 249.Fiorellini JP, Chen PK, Nevins M, Nevins ML. Int J Periodontics Restorative Dent. 2000;20:366. [PubMed] [Google Scholar]
  • 250.Ostman P-O, Hellman M, Albrektsson T, Sennerby L. Clin Oral Impl Res. 2007;18:409. doi: 10.1111/j.1600-0501.2007.01346.x. [DOI] [PubMed] [Google Scholar]
  • 251.Albrektsson T. Annual Meeting of the Academy of Dental Materials; Trieste (Italy). 2010. Editon edn. [Google Scholar]
  • 252.Svanborg LM, Andersson WAMM. J Biomed Mater Res B Appl Biomater. 2010;92:462. doi: 10.1002/jbm.b.31538. [DOI] [PubMed] [Google Scholar]
  • 253.Wennerberg A, Albrektsson T. Clin Oral Implants Res. 2009;4:172. doi: 10.1111/j.1600-0501.2009.01775.x. [DOI] [PubMed] [Google Scholar]
  • 254.Marshall SJ, Bayne SC, Baier R, Tomsi AP, Marshall GW. Dent Mater. 2010;26:e11. doi: 10.1016/j.dental.2009.11.157. [DOI] [PubMed] [Google Scholar]
  • 255.Popat KC, Eltgroth M, Desai TA. Small. 2007;3:1878. doi: 10.1002/smll.200700412. [DOI] [PubMed] [Google Scholar]
  • 256.Redey SA, Razzouk S, Rey C, Bernache-Assollant D, Leroy G, Nardin M, Cournot G. J Biomed Mat Res. 1999;45:140. doi: 10.1002/(sici)1097-4636(199905)45:2<140::aid-jbm9>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  • 257.Wei J, Yoshinari M, Takemoto S, Hattori M, Kawada E, Liu B, Oda Y. J Biomed Mat Res B Appl Biomater. 2007;81:66. doi: 10.1002/jbm.b.30638. [DOI] [PubMed] [Google Scholar]
  • 258.Brandon S, Haimovich N, Yeger E, Marmur A. J Colloid Interface Sci. 2003;263:237. doi: 10.1016/s0021-9797(03)00285-6. [DOI] [PubMed] [Google Scholar]
  • 259.Marmur A. Soft Matter. 2006;2:12–17. doi: 10.1039/b514811c. [DOI] [PubMed] [Google Scholar]
  • 260.Meiron TS, Marmur A, Saguy IS. J Colloid Interface Sci. 2004;274:637. doi: 10.1016/j.jcis.2004.02.036. [DOI] [PubMed] [Google Scholar]
  • 261.Choudhary S, Haberstroh KM, Webster TJ. Tissue Eng. 2007;13:1421. doi: 10.1089/ten.2006.0376. [DOI] [PubMed] [Google Scholar]
  • 262.Fine E, Zhang L, Fenniri H, Webster TJ. Int J Nanomedicine. 2009;4:91. doi: 10.2147/ijn.s5589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 263.Lewis G. Journal of Biomedical Materials Research Part B: Applied Biomaterials. 2008;86B:569. doi: 10.1002/jbm.b.31028. [DOI] [PubMed] [Google Scholar]
  • 264.Kukreja N, Onuma Y, Daemen J, Serruys PW. Pharmacological Research. 2008;57:171. doi: 10.1016/j.phrs.2008.01.012. [DOI] [PubMed] [Google Scholar]
  • 265.Yang L, Webster TJ. Expert Opin Drug Deliv. 2009;6:851. doi: 10.1517/17425240903044935. [DOI] [PubMed] [Google Scholar]
  • 266.Naguib N, Ye H, Gogotsi Y, Yazicioglu AG, Megaridis CM, Yoshimura M. Nano Lett. 2004;4:2237. [Google Scholar]
  • 267.Clair S, Variola F, Kondratenko M, Jedrzejowski P, Nanci A, Rosei F, Perepichka DF. J Chem Phys. 2008;128:144705. doi: 10.1063/1.2876421. [DOI] [PubMed] [Google Scholar]
  • 268.Avila G, Misch K, Galindo-Moreno P, Wang HL. Implant Dent. 2009;18:17. doi: 10.1097/ID.0b013e318192cb7d. [DOI] [PubMed] [Google Scholar]
  • 269.Palmieri A, Pezzetti F, Brunelli G, Martinelli M, Muzio LL, Scarano A, Degidi M, Piattelli A, Carinci F. Implant Dent. 2008;17:100. doi: 10.1097/ID.0b013e318166d182. [DOI] [PubMed] [Google Scholar]
  • 270.Mizuno M, Fujisawa R, Kuboki Y. J Cell Physiol. 2000;184:207. doi: 10.1002/1097-4652(200008)184:2<207::AID-JCP8>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  • 271.Reyes CD, Petrie TA, Burns KL, Schwartz Z, García AJ. Biomaterials. 2007;28:3228. doi: 10.1016/j.biomaterials.2007.04.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 272.Dalby MJ, Gadegaard N, Tare R, Andar A, Riehle MO, Herzyk P, Wilkison CDW, Oreffo ROC. Nat Mater. 2008;6:997. doi: 10.1038/nmat2013. [DOI] [PubMed] [Google Scholar]
  • 273.Hodgkinson T, Yuan XF, Bayat A. Expert Rev Med Devices. 2009;6:621. doi: 10.1586/erd.09.48. [DOI] [PubMed] [Google Scholar]
  • 274.Webster TJ, Ergun C, Doremus RH, Siegel RW, Bizios R. J Biomed Mater Res. 2000;51:475. doi: 10.1002/1097-4636(20000905)51:3<475::aid-jbm23>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]

RESOURCES